Endometriosis: where are we and where are we going?

in Reproduction
Correspondence should be addressed to K A Burns; Email: Katherine.Burns@uc.edu

(A D Greene and S A Lang contributed equally to this work)

Endometriosis currently affects ~5.5 million reproductive-aged women in the U.S. with symptoms such as painful periods (dysmenorrhea), chronic pelvic pain, pain with intercourse (dyspareunia), and infertility. It is defined as the presence of endometrial tissue outside the uterine cavity and is found predominately attached to sites within the peritoneal cavity. Diagnosis for endometriosis is solely made through surgery as no consistent biomarkers for disease diagnosis exist. There is no cure for endometriosis and treatments only target symptoms and not the underlying mechanism(s) of disease. The nature of individual predisposing factors or inherent defects in the endometrium, immune system, and/or peritoneal cavity of women with endometriosis remains unclear. The literature over the last 5 years (2010–2015) has advanced our critical knowledge related to hormones, hormone receptors, immune dysregulation, hormonal treatments, and the transformation of endometriosis to ovarian cancer. In this review, we cover the aforementioned topics with the goal of providing the reader an overview and related references for further study to highlight the progress made in endometriosis research, while concluding with critical areas of endometriosis research that are urgently needed.

Abstract

Endometriosis currently affects ~5.5 million reproductive-aged women in the U.S. with symptoms such as painful periods (dysmenorrhea), chronic pelvic pain, pain with intercourse (dyspareunia), and infertility. It is defined as the presence of endometrial tissue outside the uterine cavity and is found predominately attached to sites within the peritoneal cavity. Diagnosis for endometriosis is solely made through surgery as no consistent biomarkers for disease diagnosis exist. There is no cure for endometriosis and treatments only target symptoms and not the underlying mechanism(s) of disease. The nature of individual predisposing factors or inherent defects in the endometrium, immune system, and/or peritoneal cavity of women with endometriosis remains unclear. The literature over the last 5 years (2010–2015) has advanced our critical knowledge related to hormones, hormone receptors, immune dysregulation, hormonal treatments, and the transformation of endometriosis to ovarian cancer. In this review, we cover the aforementioned topics with the goal of providing the reader an overview and related references for further study to highlight the progress made in endometriosis research, while concluding with critical areas of endometriosis research that are urgently needed.

Introduction

Endometriosis is an estrogen-dependent gynecological condition characterized by the presence and growth of ectopic endometrial tissue, often associated with inflammation, severe and chronic pain, and infertility (Hickey et al. 2014). Lesions identified during laparoscopy are categorized as superficial peritoneal lesions, endometriomas, or deep infiltrating nodules, with high degree of individual variability in lesion color, size, and morphology. Histopathological analysis requires the presence of at least two features for a diagnosis of endometriosis, the features being endometrial epithelium, endometrial glands, endometrial stroma, and hemosiderin-filled macrophages (Hsu et al. 2010). Retrograde menstruation, in which uterine epithelial and stromal cells are disseminated and implanted into the peritoneal cavity via the fallopian tubes, is the most accepted mechanism for the pathogenesis of endometriosis (Sampson 1927b, Ahn et al. 2015a). More than 90% of women undergo retrograde menstruation; however, the prevalence of endometriosis in the general population is 6–10% (Sampson 1927a, Syrop & Halme 1987). Such a discrepancy between these two values suggests that women who develop endometriosis are likely to have other genetic, biochemical, and pathophysiological factors contributing to development of the disease (Ahn et al. 2015a).

The goal of this review is to provide a broad overview of the advancements in endometriosis research over the last 5 years (2010–2015). First, we delve into animal models often used in endometriosis research. After which, we cover critical areas of endometriosis study, including basic and clinical research, and the transformation of endometriosis into ovarian cancer. Within basic research, we focus on angiogenesis, cytokine/chemokine expression, and hormones and their receptors, and the significance they may play in the pathogenesis of endometriosis. This review is a synopsis of important findings for researchers to quickly find relevant sources of interest to his/her studies.

Animal research models

The use of animal models in the study of endometriosis allows for the control of numerous variables related to pathogenesis and disease progression, including angiogenesis, inflammation, and hormonal response. Nonhuman primate and rodent models are the most common animal models used, while the chicken chorioallantoic membrane model has limited use.

Nonhuman primate models

Nonhuman primates (baboons and rhesus macaques) are often used to study pathogenesis, progression, and treatment of endometriosis. While primates can spontaneously develop endometriosis at a low prevalence (D’hooghe et al. 1996, Zondervan et al. 2004, King et al. 2016), techniques have been developed to increase disease incidence. Cervical occlusion to promote retrograde menstruation (Scott et al. 1953, D’Hooghe et al. 1994) and a homologous model, in which endometrial tissue is excised from a donor primate and surgically transplanted or injected into a recipient primate, are used (Te Linde & Scott 1950, D’Hooghe et al. 1995, Sillem et al. 1996). Primate models, including advantages and disadvantages, have been described previously (Tirado-Gonzalez et al. 2010, Grummer 2012, King et al. 2016).

Rodent models

Rodents are often used in endometriosis research due to quick generation time, ability for genetic manipulation, and relatively low cost, especially in comparison to nonhuman primate models. Rodent models of endometriosis are divided into two main groups: heterologous or homologous/autologous models. Heterologous models use human tissue transplanted into immunocompromised mice, while homologous models involve transferring endometrial tissue from one animal to a syngeneic animal (Tirado-Gonzalez et al. 2010, King et al. 2016).

Heterologous models involve the transfer of human endometrial tissue into an immunocompromised rodent, such as athymic nude, severe combined immunodeficient (SCID), or Rag2γ(c) mice, to prevent the rodent immune system from attacking the foreign tissue (Zamah et al. 1984, Aoki et al. 1994, Greenberg & Slayden 2004). Once human tissue is collected, it is disseminated via intraperitoneal or subcutaneous injection into the immunocompromised rodent. Heterologous rodent models with associated advantages and disadvantages have been described (Tirado-Gonzalez et al. 2010, Bruner-Tran et al. 2012, Grummer 2012, King et al. 2016).

Several homologous rodent models are utilized in endometriosis research, and the generation of these models involves several important considerations regarding the reproductive status of the donor and recipient, transplantation method, and potential genetic manipulation (King et al. 2016). Often, the recipient rodents are ovariectomized and treated with estrogens to promote lesion growth (Cummings & Metcalf 1995, Somigliana et al. 1999, Styer et al. 2008, Burns et al. 2012). Critically valuable for the study of endometriosis is that the homologous model maintains an intact immune system. A large difference between homologous models is the method of transplantation and tissue dissemination. Various models exist for the development of ectopic lesions, including: (1) suturing uterine tissue into the peritoneal wall or intestinal mesentery; (2) injecting minced uterine tissue intraperitoneally to disperse freely and attach at sites within the peritoneal cavity; (3) using entire uterine tissue or endometrial tissue; and (4) using minced “menstruated” tissue for intraperitoneal injection (Vernon & Wilson 1985, Somigliana et al. 1999, Burns et al. 2012, Greaves et al. 2014). For models used to study endometriosis, it is critically important to remember the definition of and requirements for an endometriotic lesion. Discouragingly, some models inherently do not fulfill these criteria and are suboptimal for the study of endometriosis, ultimately occluding comprehensive comparison and interpretation of data in the scientific literature.

Chicken chorioallantoic membrane model

The chicken chorioallantoic membrane (CAM) assay is used to study molecular processes involved in adhesion, invasion, and angiogenesis of developing endometriotic lesions. This assay involves culturing human endometrial tissue on the CAM of fertilized chicken embryos (Maas et al. 2001). The CAM has a dense microvasculature, useful for examining angiogenesis and for experimentation with anti-angiogenic agents (Nap et al. 2005). This method has been used to study the impact of matrix metalloproteinase (MMP) expression and activity on adhesion and invasion (Nap et al. 2004, Juhasz-Boss et al. 2010). However, it is not suited for studying immunological or inflammatory aspects of lesion development or for potential effects of systemic treatments.

Pathogenesis and progression of endometriosis

Animal models and human samples are paramount in the study of pathogenesis and progression of endometriosis. They allow for in-depth analysis of factors involved in this disease, including inflammation, angiogenesis, cytokine/chemokine expression, and endocrine alterations such as steroid and steroid receptor expression. These components also form a complex, interacting system greatly impacting the development of endometriosis. While we understand that several other factors are involved in the pathogenesis and progression of this disease, including genetics and epigenetics, and significant advances in these components have been made, covering them in depth is beyond the scope of this review. For researchers interested in these topics, an elegant and comprehensive review by Bulun and coworkers (2015) recently addresses the molecular biology, genetics, and epigenetics of endometriosis and covers 25 years of research (1990–2015).

Inflammation – angiogenesis

Angiogenesis is the formation of new blood vessels, and subsequently, is a key process to form functional blood vessels to ectopic menstrual tissue for the establishment/maintenance of endometriotic lesions. Theorized is that women with endometriosis respond to retrograde menstrual tissue as a “wound” that must be healed and not as “self” that must be removed (Herington et al. 2011). Examining key players involved in angiogenesis, both in women with endometriosis and in animal models, similarities between angiogenesis in endometriotic lesions and angiogenesis in wound healing exist. A variety of growth factors and genes related to angiogenesis have been studied in endometriosis.

The VEGF protein family is well known for roles in angiogenesis, vasculogenesis, and lymphangiogenesis. Human peritoneal fluid (PF) from women with endometriosis show inconsistent protein levels of VEGF, but this may be due to sample size, dilution of PF, or true variability among women. For example, some studies show increased VEGF levels in the PF (Bourlev et al. 2010, Xu et al. 2013, Szubert et al. 2014); however, other studies show no increase in VEGF levels in women with endometriosis compared with healthy women (Barcz et al. 2012, Bersinger et al. 2012, Rathore et al. 2014). Interestingly, more consistency is found in animal models of endometriosis, most likely because of controlled onset of experimental conditions. A variety of rodent models of endometriosis show VEGF levels increase in endometriosis-like lesions (Machado et al. 2010, Ricci et al. 2011, Kumar et al. 2014, Lu et al. 2014a, Machado et al. 2014, Zhao et al. 2015). Data are inconsistent when attempting to target VEGF in the mouse to treat endometriosis (Xu et al. 2011, Novella-Maestre et al. 2012, Virani et al. 2013, Kumar et al. 2014); however, the data suggest that VEGF drives angiogenesis in endometriosis. Furthermore, these results from human and animal models demonstrate challenges of clearly deciphering VEGF as an appropriate marker for endometriosis.

Other angiogenic factors play important roles in the adhesion and maintenance of endometriosis lesions, including hypoxia factors (i.e. HIF1A), MMPs (i.e. MMP9), and microRNAs (miRNA). As mentioned, the peritoneal microenvironment of women with endometriosis is often different from healthy women. In a heterologous mouse model, hypoxic conditions promote angiogenesis and proliferation of endometriosis demonstrated by larger lesions, higher levels of VEGF, HIF1A, Ki67, and PECAM1 (Lu et al. 2014b). Concomitantly, the same group shows that lesion location affects adhesion and angiogenesis when comparing intraperitoneal versus subcutaneous endometriotic tissue injection (Lu et al. 2014a), suggesting that the microenvironment of the peritoneal cavity plays a crucial role in lesion adhesion and angiogenesis. MMPs are proteases required for reorganizing existing blood vessels during budding angiogenesis (Page-McCaw et al. 2007). Recently, the role of MMPs in endometriosis were not studied in-depth, but MMPs play a known role in endometriosis (Machado et al. 2010). For example, Mmp92/2 uterine tissue does not grow in a mouse suture endometriosis model (Han et al. 2012); however, this model does not account for actual tissue attachment. An emerging field in endometriosis is the function of miRNA in angiogenesis. Primary eutopic and ectopic endometrial stromal cells exposed to PF from women with endometriosis have downregulated miRNAs known to regulate VEGF expression compared with cells exposed to PF from control women (Braza-Boils et al. 2013, 2014, 2015). Future in-depth analysis of the interplay between inflammation and angiogenesis in the early stages of endometriosis development is needed to determine which molecules could potentially be targeted therapeutically.

Inflammation – cytokine and chemokine expression

Cytokines and chemokines are emerging as key players in endometriosis pathobiology. Cytokines are a broad group of secreted proteins important in cell signaling, while chemokines are a family of cytokines important in inducing chemotaxis in nearby cells. A complete overview of chemokines and cytokines in endometriosis is too exhaustive; however, these proteins are altered in PF, ectopic lesions, eutopic endometrium, and serum. To demonstrate the growing role of cytokine research in the study of endometriosis, Table 1 lists cytokines and chemokines that appear in more than two endometriosis research papers between 2010 and 2015. Additional to the dysregulation of cytokines/chemokines, altered levels of a large number of cytokines/chemokines are found in cyst fluid removed from endometriomas/chocolate cysts (Chen et al. 2013b). Before elucidating the interplay and implications of chemokines and cytokines in endometriosis, large-scale-controlled human studies or meta-analyses will need to be conducted to fully encompass cytokine dysregulation. Most likely, with the signaling complexity of the immune system and endometriosis as a disease, a single chemokine/cytokine will not diagnose disease, but instead, a disease profile of altered cytokines may be used to establish disease diagnosis. Furthermore, as nicely outlined by Fassbender and coworkers, international standardized methods for BioBanking endometriosis samples needs to be implemented (Fassbender et al. 2013).

Table 1

Cytokine or chemokine alterations in endometriosis.

Cytokine/chemokineModelResultsReference
CCL2 (MCP-1)hPF+, ++, +++(Mier-Cabrera et al. 2011, Margari et al. 2013), (Tao et al. 2011), (Bersinger et al. 2012)
CCL5 (RANTES)hPFns, +, ++(Bersinger et al. 2012, Margari et al. 2013), (Mier-Cabrera et al. 2011), (Beste et al. 2014)
hEctopicQualitative +, ++(Wang et al. 2010), (Yang et al. 2013)
CCL11 (Eotaxin)hPF++, +(Bersinger et al. 2012), (Mier-Cabrera et al. 2011)
CXCL1 (GROa)hPFNearing(Bersinger et al. 2012)
CXCL8 (IL8)hPFns,+, ++(Velasco et al. 2010, Bersinger et al. 2012), (Mier-Cabrera et al. 2011, Beste et al. 2014), (Milewski et al. 2011, Malhotra et al. 2012)
hSerum++(Carmona et al. 2012)
hEESCs++(Delbandi et al. 2013)
hPF mRNA CellsNS(Yeo et al. 2013)
CXCL10 (IP-10)hLesionns trend –(Bellelis et al. 2013)
hPF++(Bersinger et al. 2012)
CXCL12 (SDF1)hEctopic+(Bellelis et al. 2013)
hPF+(Leconte et al. 2014)
IL1BhPF+, +++(Mier-Cabrera et al. 2011, Beste et al. 2014), (Sikora et al. 2012)
hEctopic+(Chen et al. 2013)
hPF cellsns(Yeo et al. 2013)
IL4hPFns, ++(Mier-Cabrera et al. 2011, Wickiewicz et al. 2013), (Beste et al. 2014)
IL6hPFns, +, ++, +++(Rathore et al. 2014), (Mier-Cabrera et al. 2011, Khan et al. 2015), (Velasco et al. 2010, Kang et al. 2014), (Milewski et al. 2011, Bersinger et al. 2012, Podgaec et al. 2012, Wickiewicz et al. 2013)
hSerum+, ++, +++(Kinugasa et al. 2011), (Carmona et al. 2012), (Elgafor El Sharkwy 2013)
hEESC++(Delbandi et al. 2013)
hPF mRNA Cellsns(Yeo et al. 2013)
IL10hSerum/PFns/ns(Andreoli et al. 2011)
hPFns, +(Bersinger et al. 2012, Podgaec et al. 2012), (Mier-Cabrera et al. 2011, Wickiewicz et al. 2013)
hPF mRNA Cellsns(Yeo et al. 2013)
IL12hSerum/PFns/ns(Andreoli et al. 2011)
hPFns(Mier-Cabrera et al. 2011)
hPF mRNA Cellsns(Yeo et al. 2013)
IL17AhEndo, Serum**/+(Ahn et al. 2015)
hSerum/PFns/ns(Andreoli et al. 2011)
hPFns(Podgaec et al. 2012)
hFF/Serum+++/+++(Sabbaghi et al. 2014)
IL18hPF+, −−−(Bersinger et al. 2012), (Sikora et al. 2012)
IL22hEctopic**(Guo et al. 2013)
hSerum− (Santulli et al. 2013)
IFNGhPFns, +(Wickiewicz et al. 2013), (Mier-Cabrera et al. 2011)
hPF mRNA Cellsns(Yeo et al. 2013)
MIFhPF++(Beste et al. 2014)
hEctopic++(Lin et al. 2010)
TGFBhPF+++(Podgaec et al. 2012)
mKO w/human− size(Hull et al. 2012)
TNFAhPFns, +, ++(Tao et al. 2011, Wickiewicz et al. 2013), (Mier-Cabrera et al. 2011, Beste et al. 2014, Young et al. 2014a,b), (Khan et al. 2015)
hEctopic cd56++(Chen et al. 2013)
pfNKcell+(Funamizu et al. 2014)
bEctopicns(Ilad et al. 2010)
hPF mRNA Cellsns(Yeo et al. 2013)

Increased levels: +P<0.05, +P<0.01, +P<0.001

qualitative IHC. Decreased levels: −P<0.05. ns, nonsignificant; h, human; b, baboon; Ectopic, ectopic endometriosis lesion; PF, peritoneal fluid; FF, follicular fluid; EESC, ectopic endometrial stromal cells.

Hormones and hormone receptors

Endometriosis is intimately associated with steroid metabolism and associated pathways, corresponding to the paramount roles estrogen receptors (ESRs) and progesterone receptors (PGRs) play in uterine biology. Both human and animal model studies show endometriosis is estrogen (E2) dependent and is regulated through the ERs alpha and beta (ESR1 and ESR2) (Burns et al. 2012, Pellegrini et al. 2012, Wu et al. 2012, Han et al. 2015, Zhao et al. 2015). An increased ratio of ESR2 to ESR1 mRNA is observed in endometriomas compared with endometriosis implants and eutopic endometrium (Bukulmez et al. 2008). Knockout studies in mice show that lesion attachment, size, and proliferation are closely associated with the presence or absence of Esr1 and Esr2 (Burns et al. 2012). The Bulun Laboratory has focused efforts on ESR2 and demonstrates that ESR2 expression is highly increased in endometriotic tissue due to hypomethylation of the promoter region (Dyson et al. 2014). They also identify RAS-like estrogen-regulated growth inhibitor (RERG) as a key enzymatic target of estradiol signaling through ESR2. This enzyme regulates numerous factors involved in the progression of endometriosis, including cell proliferation and apoptotic resistance (Monsivais et al. 2014). Additionally, they have nicely detailed multiple studies on the role of ESR2 in endometriosis in a comprehensive review (Bulun et al. 2012). Use of estrogen receptor ligands, inhibitors, and agonists also support the role of ESRs in endometriosis (Colette et al. 2011, Kulak et al. 2011, Han et al. 2012, Chen et al. 2014, Naqvi et al. 2014, Zhao et al. 2015, Palmer et al. 2016). Specifically, selective estrogen receptor modulators (SERMs) are synthetic molecules which bind to ESRs and act as either antagonists or agonists. Two compounds, chloroindazole (CLI) and oxabicycloheptene sulfonate (OBHS), have strong ER-dependent anti-inflammatory effects on endometriosis lesions in vivo in a suture mouse model of endometriosis and in vitro, with primary human endometriotic stromal cells (Zhao et al. 2015). Their data suggest that both CLI and OBHS inhibit the establishment of new lesions and reduce the size of already established lesions; however, important next studies using these inhibitors will be to examine lesion attachment without a suture endometriosis model, as suturing alone creates an unnecessary inflammatory response similar to any reaction toward a foreign body (Carr et al. 2009) and, in some respects, negates the use of homologous tissue.

Progesterone (P4) and its receptor isoforms, PGR-A and -B, also have established roles in endometriosis. The endometrium of women with endometriosis demonstrates an attenuated response to P4 because PGR-responsive genes are not suppressed in the eutopic endometrium of women with endometriosis compared with healthy women in the early secretory phase of the menstrual cycle, suggesting the presence of a progesterone resistance phenotype in these women (Burney et al. 2007). A more recent study to discriminate between the PGR isoforms finds elevated levels of PGR-A in endometriosis lesions and eutopic endometrium from women with endometriosis and shows a PGR-A-dominant state, regardless of menstrual phase (Bedaiwy et al. 2015). While the data are from a small cohort of women, their findings suggest that a PGR-A-dominant menstrual efflux in the peritoneal cavity may mirror the growth and invasive properties known about cancers overexpressing PGR-A.

Aromatase is the enzyme responsible for the aromatization of androgens into estrogens. Aromatase protein level is increased in vaginal septum lesions and decreased in intestinal lesions in women with endometriosis (Goncalves et al. 2015). Ovarian endometriomas express higher levels of aromatase and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PPARGC1A) than associated ectopic lesions and eutopic endometrium (Suganuma et al. 2014). Activation of peroxisome proliferator-activated receptor gamma (PPARG) inhibits the growth and survival of human endometriotic cells by suppressing E2 biosynthesis and prostaglandin E2 (PGE2) signaling (Lebovic et al. 2013). The use of AIs for the treatment of endometriosis is becoming more common and is discussed below.

The last 5 years have expanded our knowledge of hormones, hormone receptors (HRs), and associated coregulators. These studies are important for integrating dysregulation found in ectopic lesions, but also have allowed for the design of more targeted areas to be studied. More in-depth studies with targeted HR uterine knockouts, coregulator knockouts, and/or with the recently synthesized SERMS will lead to greater understanding of the role of HR in disease. The results of these future experiments will allow for even more targeted experiments and hopefully development and use of more targeted therapeutic paradigms.

Interactions between inflammation and the endocrine system

Crosstalk between the immune/inflammatory and endocrine systems can significantly impact pathogenesis and progression of endometriosis. The sex hormone receptors can markedly alter the immune response in ectopic tissue. Both ESR1 and ESR2 have distinct roles in regulating the immune response, as discovered through the use of multiple animal models. Signaling of E2 through ESR1 appears to have both an anti- and pro-inflammatory roles, as observed by increased mitogenesis and decreased IFNG, TNF, and IL12 transcript expression (Burns et al. 2012). Overexpression of ESR2 activates the inflammasome and modulates TNF-induced apoptosis, as observed with increases in IL1B and cleaved caspase-1 levels and decreases in cleaved caspase-8 levels in ectopic lesions (Han et al. 2015).

Hormones themselves also directly alter the immune system. Monocyte chemotactic factor-1 (MCP1/CCL2) is an example of a chemokine significantly affected by sex hormones. In human endometrial endothelial cells from women with endometriosis, both E2 and P4 increase MCP1 mRNA and protein expression; this effect is not observed in cells from healthy women (Luk et al. 2010). After treating monocytes with control peritoneal fluid (cPF) or endometriotic peritoneal fluid (ePF), the addition of E2 to the culture suppresses MCP1 release from cPF-treated monocytes. However, E2 does not suppress MCP1 release from ePF-treated monocytes (Lee et al. 2012). E2 promotes a pro-inflammatory environment by increasing the secretion of IL6 and TNF from peritoneal macrophages from women with endometriosis compared with control women. This effect is further enhanced by co-treatment with lipopolysaccharide (Khan et al. 2015). Other chemokines, CXCR4 and CXCL12, are downregulated by sex hormones in human epithelial endometrial cells and human endometrial stromal cells, respectively (Ruiz et al. 2010). All of these findings provide evidence that the immune environment and its response to sex hormones is altered in women with endometriosis; however, a definitive mechanism for these differences is largely unknown and is a major area that future research needs to address.

A third aspect to the endocrine-immune crosstalk involves aromatase expression. Macrophage migration inhibitory factor (MIF) increases aromatase mRNA and protein expression in ectopic endometrial stromal cells via post-transcriptional stabilization (Veillat et al. 2012). Interestingly though, E2 treatment in the same cells increases MIF mRNA and protein expression, suggesting a positive feedback loop between the endocrine and immune systems in women with endometriosis (Veillat et al. 2012). Potential for a continuous positive-feedback loop between these systems is an area for further exploration to understand the dynamic and altered environment in women with endometriosis.

Clinical symptoms and diagnosis of endometriosis

Endometriosis is often characterized by pelvic pain that manifests in a variety of ways; most commonly, patients present with dysmenorrhea, noncyclical pelvic pain, and dyspareunia, but other common symptoms are dyschezia, dysuria, and infertility (Fritz MA 2011, Practice Committee of the American Society for Reproductive 2014). Definitive diagnosis of endometriosis is by visualization or excision of lesions via laparoscopy. The American Society for Reproductive Medicine (ASRM) grading system for endometriosis guides surgeons in determining the severity of disease (American Society for Reproductive Medicine 1997) and was created to help predict pregnancy with fertility treatment. The grading system does not correlate with pain level, and has limited reproducibility to predict pregnancy; however; it remains the best objective to communicate disease severity between physicians and surgeons.

Accuracy of visual diagnosis increases with disease severity (Fernando et al. 2013). While the European Society of Human Reproduction and Embryology (ESHRE) requirements suggest that surgical diagnosis by visualization alone is appropriate, ASRM stresses that biopsies be taken when diagnosis is unclear (Fernando et al. 2013). Importantly, poor correlation exists between clinical symptoms and disease burden (Dunselman et al. 2014, Practice Committee of the American Society for Reproductive 2014). Diagnosing endometriosis by pelvic pain alone is not sufficient, as pelvic pain is also a symptom of many other diseases, including pelvic adhesions, adenomyosis, and gastrointestinal urologic disorders (Bulun 2009, Practice Committee of the American Society for Reproductive 2014). This vast differential diagnosis for pelvic pain can complicate the diagnosis of endometriosis.

Treatments

Several different treatment modalities, including medical, surgical, and alternative, exist for endometriosis. First-line medical management includes options that have a favorable safety and cost profile, that are well tolerated by the patient, and that are effective in treatment (Zito et al. 2014). If medical therapy fails, surgical therapy to remove endometriotic lesions and endometriomas is performed. Finally, alternative therapies are being used to supplement conventional treatments.

Medical therapy

Combined oral contraceptive pills (OCPs), which include ethinyl estradiol (EE) and various progestins, are used to treat endometriosis, particularly in women not trying to conceive (Practice Committee of the American Society for Reproductive 2014, Zito et al. 2014). Historically, OCPs have been first-line therapy, but most studies are decades old and the pills contained higher doses of EE. Based on a more recent randomized control trial (RCT) in 100 patients, low-dose OCPs decrease pain more significantly than placebo on the Visual Analog Scale (VAS) (Harada et al. 2008). Continuous OCPs decrease recurrence rates of dysmenorrhea after surgical therapy when compared with cyclic OCPs (Zorbas et al. 2015, Muzii et al. 2016). Of the progestins, the 19-nortestosterone derivatives are less androgenic and offer better side-effect profiles (Angioni et al. 2014). In an RCT, dienogest significantly decreases endometriosis-related pain similar to gonadotropin-releasing hormone agonists (GnRHa), both as initial and postoperative therapy, without the negative side-effect profile of GnRHa (Angioni et al. 2014, Andres Mde et al. 2015, Granese et al. 2015, Strowitzki et al. 2015). Levonorgestrel, delivered through an intrauterine system after conservative surgery, significantly decreases dysmenorrhea, dyspareunia, and noncyclic pelvic pain compared with expectant management in an RCT of 55 patients (Tanmahasamut et al. 2012, Imai et al. 2014).

Several therapies aim to create a hypoestrogenic state in women with endometriosis. Examples of these treatments include GnRHa, GnRH antagonists (GnRH-ant), synthetic androgens, and AIs. GnRHa therapy downregulates gonadotropin receptors and desensitizes the body to gonadotropins. It decreases pain and endometriotic nodules in comparison to placebo (Leone Roberti Maggiore et al. 2014, Brown & Farquhar 2015). A multicenter RCT comparing GnRHa to OCPs as postsurgical therapy reports that both groups increase quality of life scores (Granese et al. 2015). Although GnRHa is proven effective, a severe side effect is decreased bone mineral density (BMD); therefore, estrogens or progestins are given for bone protection (Leone Roberti Maggiore et al. 2014, Zito et al. 2014). In contrast, GnRH-ant inhibits gonadotropin receptors. Elagolix improves dysmenorrhea and dyspareunia compared with placebo in a phase 2 RCT (Ezzati & Carr 2015, Munoz-Hernando et al. 2015), and comparing BMD profiles of elagolix with depot medroxyprogesterone acetate, both minimally impact BMD (Carr et al. 2014, Ezzati & Carr 2015).

Danazol, a synthetic androgen, inhibits the luteinizing hormone (LH) surge; however, it also increases free testosterone, causing undesired side effects including hirsutism, deepening of voice, weightgain, and acne. Danazol effectively decreases pelvic pain compared with placebo, and is as effective as other hormonal therapies, but the numerous side effects limit the use (Practice Committee of the American Society for Reproductive 2014, Zito et al. 2014). AIs are currently a second-line treatment in women refractory to first-line treatments (Abu Hashim 2014). AIs such as letrozole decrease estrogen stimulation of endometriosis and, when used in combination with GnRHa, improve pelvic pain more than GnRHa alone. Additionally, letrozole with norethindrone acetate add-back has improved endometriosis symptoms, and high dose aromatase inhibition reduces ovarian endometrioma size (Agarwal et al. 2015). In contrast, a small RCT investigating postsurgical endometriosis pain comparing OCPs alone and in combination with letrozole reports similar pain scores, suggesting no benefit with letrozole addition (Almassinokiani et al. 2014).

Surgical therapy

Surgical therapy for endometriosis is typically necessary for intractable pelvic pain despite medical therapy. Several different surgical techniques are performed (Table 2), including excision/removal of endometriosis, uterosacral nerve ablation, presacral neurectomy, and hysterectomy with bilateral salpingo-oophorectomy (BSO) (Daniels et al. 2010, Healey et al. 2014, Posadzka et al. 2015), and some techniques provide better symptomatic control than others. For symptom improvement and preventing disease recurrence, endometrioma removal is superior to drainage (Duffy et al. 2014, Practice Committee of the American Society for Reproductive 2014). Hysterectomy without BSO is less effective because of continued hormonal stimulation of microscopic endometriotic lesions. Hysterectomy with BSO leads to surgical menopause, which negatively impacts bone and cardiac health. Extreme surgical management is reserved for patients who fail conservative management (Duffy et al. 2014, Practice Committee of the American Society for Reproductive 2014).

Table 2

Endometriosis surgical treatments and associated efficacy.

Surgical treatmentSurgical techniqueCompared treatmentEfficacy
Laparoscopic ablationAblate, or apply heat, to lesionCO2 laser vs electric cauteryDecreased pain with ablation (NRS 3) vs CO2 laser (NRS) (Posadzka et al. 2015)
Diagnostic laparoscopyDecreased overall pain OR 5.63 (Duffy et al. 2014)
Laparoscopic excisionRemove lesion with scissor or laserAblationNo difference in overall pain, dyspareunia, or dyschezia at 1 year (Bulun 2009, Duffy et al. 2014)
Excision decreased dyspareunia (VAS 3.2) vs ablation (VAS 6.0) at 5 years (Healey et al. 2014)
Ablation required more medical treatment (31%) vs excision (20%) (Healey et al. 2014)
Conservative laparoscopyAblate or excise lesions, restore anatomy, adhesiolysisDiagnostic laparoscopyDecreased overall pain OR 6.58 (Duffy et al. 2014)
Laparoscopic uterosacral nerve ablationAblate nerve fibers responsible for pain pathwayConservative laparoscopyNo difference in pain level (Daniels et al. 2010)
Endometrioma removalSeparate cyst wall from ovary and excise cystCyst drainageDecreased recurrence of cyst (Dunselman et al. 2014)
Decreased recurrence of dysmenorrhea (OR 0.15) (Brown & Farquhar 2015)
Presacral neurectomyDisrupts sympathetic innervation of uterus at level of superior hypogastric plexusConservative laparoscopy1 RCT: decrease midline dysmenorrhea (Practice Committee of the American Society for Reproductive 2014) (Dunselman et al. 2014)
1 RCT: no additional benefit (Practice Committee of the American Society for Reproductive 2014)
Hysterectomy+BSODebulking to place in surgical menopauseHysterectomy without BSOImproved symptoms (Practice Committee of the American Society for Reproductive 2014) (Dunselman et al. 2014) (Duffy et al. 2014)

BSO, bilateral salpingo-oophorectomy; VAS, visual analog scale; NRS, numeric rating scale; OR, odds ratio.

Alternative therapy

Given that endometriosis is such a difficult disease to treat, alternative therapies are welcomed in addition to conventional therapy. Comparing Chinese medicine (CM) to GnRHa as postsurgical treatment for endometriosis found no differences in recurrence rates on follow-up (Weng et al. 2015). In contrast, Chinese herbal enemas decrease dysmenorrhea comparable to danazol (Kong et al. 2014), and CM and herbal enema combination is superior to danazol in decreasing pain symptoms (Flower et al. 2012). An acupuncture study in addition to conventional medical therapy significantly decreases pelvic pain by 5–6 points on the 10-point VAS (Rubi-Klein et al. 2010). Pelvic physical therapy includes internal manual treatment to stretch pelvic floor muscles, myofascial release, biofeedback, and trigger point release. In those with myofascial chronic pelvic pain, 63% report significant pain improvement after at least 6 sessions (Bedaiwy et al. 2013). Exercise can provide pain relief, based on questionnaire studies composed of 50–2730 women with endometriosis and 400–4000 control women; however, other survey studies correlate exercise with increased pelvic pain. Unfortunately, not all of these studies are controlled and all are from self-reporting (Bonocher et al. 2014). Large prospective cohort or case-control studies demonstrate increased risk of endometriosis with diets high in trans-fatty acids and decreased risk with diets containing high levels of long-chain omega 3 fatty acids (Hansen & Knudsen 2013). More high quality studies are needed in these areas, and importantly, a positive publication selection bias likely exists with alternative therapies, exaggerating true effectiveness (Kong et al. 2014).

Association between endometriosis and cancer

The potential association between endometriosis and cancer has been theorized for decades. This association is based upon observational case-control and cohort studies that propose malignant transformation occurs within endometriotic lesions, giving rise to cancer. Our molecular-genetic understanding of both endometriosis and ovarian cancer continues to rapidly evolve; yet, a definitive mechanism for malignant transformation remains elusive.

Risk and prognosis

The 10% prevalence of endometriosis, and an even higher prevalence for women with infertility or chronic pelvic pain, makes the establishment of an absolute “cause-and-effect” relationship problematic. Lifetime risk of developing ovarian cancer in the general population is ~1.4%, with a median age of onset in the early 60s (Schorge et al. 2010). Epithelial ovarian cancer is no longer seen as a single disease, but rather a constellation of multiple diseases based upon histologic subtypes and unique molecular signatures (Galic et al. 2013). The risk of ovarian cancer increases for women who incur fewer pregnancies and/or suffer from infertility. The possibility of confounding when assessing associative risk between these two entities must be considered because infertility is related to both conditions.

Nonetheless, a number of epidemiologic and clinical features lead investigators to propose an association between endometriosis and cancer. The establishment of an association was reported 90 years ago (Sampson 1925) and was refined in 1953, proposing that benign endometriosis should be observed in close anatomic proximity to the arising endometriosis-associated cancer (Scott 1953). Chief among the observations are that both entities produce tissues that can metastasize, invade, and destroy normal surrounding tissues. Furthermore, cancers often are identified in endometriotic lesions or in tissues that are contiguous with endometriosis, and there are often findings of candidate precursor lesions exhibiting histologic atypia in these surrounding tissues (Wei et al. 2011). Finally, endometriosis in younger women, which persists into older age, creates a long window for malignant transformation.

Several retrospective studies initially document the increased rate of endometriosis in women with ovarian cancer. A Swedish study containing over 20,000 patients that cross-matched inpatient endometriosis diagnosis and any cancer diagnosis (Brinton et al. 1997) found a small increased risk of any cancer, but the risks were not confirmed upon long-term follow-up (Brinton et al. 1997). The risk of ovarian cancer, however, is significantly increased in both the initial and long-term analyses. In patients with a history of prolonged endometriosis, the statistical risk for the development of ovarian cancer is even higher.

A linkage analysis of over 99,000 women from Denmark shows that an endometriosis-related increase in ovarian cancer occurs in two histologic subtypes, clear cell and endometrioid (summarized in Table 3) (Brinton et al. 2005). Recent evidence also suggests a correlation between endometriosis and high-grade serous histologic type ovarian cancer (Lee et al. 2016). A large case-control study confirms an approximate three-fold increased risk of clear cell or endometrioid ovarian cancer in association with endometriosis (Rossing et al. 2008). Malignant transformation risk to ovarian cancer from ovarian endometriosis is reportedly 0.2–2.5% (Gadducci et al. 2014). Recent studies also show the association between endometriosis and different forms of ovarian cancer: serous, mucinous, clear cell, and endometrioid, with the predominant cell types being clear cell and endometrioid (Table 4).

Table 3

Summary of risks associated with endometriosis and cancer from registry studies by Brinton et al. (1997, 2005).

PopulationRiskSIR* or RR95% CI
History of endometriosis admission (HEA)Any cancer1.2*1.1–1.3*
HEAOvarian cancer1.9*1.3–2.8*
HEA & prolonged endometriosisOvarian cancer4.2*2.0–7.7*
HEAEndometrial cancer1.1*0.6–1.9*
HEA long-term F/UAny cancer
HEA long-term F/UOvarian cancer1.43*1.19–1.71*
Long-term F/U & prolonged endometriosisOvarian cancer2.23*1.36–3.44*
HEA Denmark cohortClear cell ovarian cancer3.371.24–9.14
HEA Denmark cohortEndometrioid ovarian cancer2.531.19–5.38

HEA, history of endometriosis admission; SIR, standardized incidence ratio; RR, relative risk; CI, confidence interval; F/U, follow-up. *denotes SIR.

Table 4

Ovarian cancer types arising from endometriosis transformation.

Population (# patients EAOC/total in study)Ovarian cancer type in EAOCAge (mean ± s.d.) yearsReference
Quebec, BC (41/2854)Serous 19.51%OC 53.9±11.4(Aris 2010)
Mucinous NREAOC 48.3±10.8
Clear cell 21.9%
Endometrioid 24.4%
Belegrade, Serbia (23/210)Serous 3.5%NR(Dzatic-Smiljkovic et al. 2011)
Mucinous NR
Clear cell 36.8%
Endometrioid 31.6%
Michigan, USA (42/184)Serous 55%OC 59(Kumar et al. 2011)
Mucinous 10%EAOC 52
Clear cell 21%
Endometrioid 14%
Athens, Greece (17)Serous 5.9%EAOC 58 (27–76)(Kondi-Pafiti et al. 2012)
Mucinous NR
Clear cell 58.8%
Endometrioid 35.3%
Ovarian Cancer Association Consortium (738/7911)Serous 7.1%OC 56.1(Pearce et al. 2012)
Mucinous 6.0%
Clear cell 20.2%
Endometrioid 13.9%
EAOC 56.3
Ankara, Turkey (45/1086)Serous 13.3%EAOC 55 (35–77)(Boyraz et al. 2013)
Mucinous 8.9%
Clear cell 37.8%
Endometrioid 33.3%
Massachusetts, USA (67/134)Serous 0%OC 56.6(Davis et al. 2014)
Mucinous NREAOC 51.7
Clear cell 38.8%
Endometrioid 61.2%
Milano, Italy (27/73)Serous NROC 58.4±11.2(Scarfone et al. 2014)
Mucinous NREAOC 51.4±10
Clear cell 76.1%
Endometrioid NR
San Juan, Puerto Rico (20/192)Serous 2.2%OC 56.1±14.9(Acien et al. 2015)
Mucinous 2.7%EAOC 48.8±11.6
Clear cell 23%
Endometrioid 50%
Shiraz, Iran (28/110)Serous 14.5%OC 50.18±12.8(Akbarzadeh-Jahromi et al. 2015)
Mucinous 0%EAOC 49.93±9.36
Clear cell 14.5%
Endometrioid 39%

OC, ovarian cancer; EAOC, endometriosis-associated ovarian cancer; NR, not reported.

A meta-analysis conducted by Kim et al. (2014) evaluates the risk and prognosis of ovarian cancer in ~445,000 women with or without endometriosis. Based on 35 studies, women with endometriosis are significantly at risk of developing ovarian cancer; however, stage is more likely to be early and low-grade, suggesting that the cancer is slow growing and less invasive. Endometrioid and clear cell are common in women with endometriosis, with the serous subtype occurring less frequently and the mucinous subtype displaying no differences between control women and women with endometriosis (Kim et al. 2014). Endometriosis does not affect prognosis, and the overall survival in women with endometriosis-associated ovarian cancer (EAOC) and in women with non-EAOC are similar when accounting for histology, disease status, assessment of endometriosis, and potential confounding factors. Unfortunately, the effect of endometriosis on a successful debulking surgery is not analyzed (Kim et al. 2014), so it is unknown if there is a benefit in survival in women with EAOC.

Proposed mechanisms of malignant transformation

Complex hormonal, genetic, and immunologic interactions must be considered when assessing the interplay between endometriosis in the development of epithelial primary peritoneal or ovarian carcinomas. Chronic inflammation, autocrine and paracrine effects, hormonal interactions, and microenvironmental alterations caused by endometriosis in the pelvic region could be relevant mechanisms for malignant transformation. Aberrant immune function, stimulated by estrogens, may create a positive-feedforward loop, enhancing growth and invasiveness of endometriosis and promoting malignant transformation (Ness 2003). Zanetta and coworkers report a role for a hyper-estrogenic state in stimulating endometriosis and promoting malignant transformation (Zanetta et al. 2000).

A permissive microenvironment and accumulation of genetic mutations is suggested to cause malignant change in endometriosis (Wei et al. 2011). Distinct molecular events may occur in early stages of tumorigenesis of endometriosis-associated carcinoma. Recent studies focus on genetic alterations such as phosphatase and tensin homolog (PTEN), tumor protein p53 (TP53), and B-cell lymphoma (BCL) gene mutations that lead to malignant changes in endometriosis (Nezhat et al. 2008, Munksgaard & Blaakaer 2012, Lai et al. 2013, McConechy et al. 2014). An interplay of genetics and oxidative stress, with decreased expression of interleukin 1 receptor type 2 (IL1R2), is a common signature between endometrioid ovarian cancer and endometriosis (Kobayashi et al. 2009, Keita et al. 2010, 2011). IL1 ligands are expressed by all endometriosis-associated ovarian cancer subtypes and endometrial cells. A decrease in IL1R1 levels, a protector against the tumorigenic effects of IL1, occurs in endometrioid carcinoma (Keita et al. 2010, 2011).

Multiple tumor-associated somatic mutations, detected by examining single gene or by whole genome sequencing, have revealed a signature of mutations. Mutations in catenin beta 1 (CTNNB1) are seen in 60% of ovarian endometrioid carcinomas (Matsumoto et al. 2015). Mutations in AT-Rich Interactive Domain 1A (ARID1A) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) appear most consistently in clear cell ovarian carcinomas (Gadducci et al. 2014, Anglesio et al. 2015, Matsumoto et al. 2015). Mutations in ARID1A, involved in chromatin remodeling, are present in both clear cell (15–75%) and endometrioid carcinomas (30–55%) (Wiegand et al. 2010, Gadducci et al. 2014). Associated with malignant transformation, mutations in ARID1A lead to the loss of its product, BAF250a, which correlates strongly with ovarian clear-cell carcinoma and endometrioid carcinoma subtypes, as well as with high-grade endometrial carcinomas (Wiegand et al. 2010, 2011, Ayhan et al. 2012, Lowery et al. 2012, Samartzis et al. 2012, Chene et al. 2015). ARID1A mutations and BAF250a loss are also observed in tumors and contiguous atypical endometriosis, but not in distant endometriotic lesions. The loss of ARID1A expression usually coexists with PI3K-Akt pathway activation and/or zinc finger protein 217 (ZNF217) amplification in ovarian clear cell cancers and may indicate an early event in the malignant transformation of endometriosis into the various histotypes of ovarian cancer (Ayhan et al. 2012, Huang et al. 2014).

Loss of PTEN is observed in clear cell-associated endometriosis and cancers, including a significant increase in expression levels of X-ray repair cross-complementing protein 5 (XRCC5), patched 2 (PTCH2), elongation factor 1-alpha 2 (EEF1A2), and protein phosphatase 1 regulatory subunit 14B (PPP1R14B). However, these changes are not observed in benign endometriosis (Worley et al. 2015). PTEN loss is proposed as an early and permissive event in endometriosis development, while loss of ESR1 and polycomb-mediated transcriptional factor cause ultimate malignant transformation (Worley et al. 2015).

Future research will clarify the likely complex interaction among genetic alterations, estrogen exposure, inflammatory cytokines, and the immunologic microenvironment in the transformation of endometriosis to endometrioid and clear cell ovarian and primary peritoneal cancers. Treatment of these cancers will hopefully improve with the use of targeted and immunologic therapies that address the underlying causes of malignant transformation.

Concluding remarks: where are we going?

While the studies reviewed from the last 5 years demonstrate a deeper understanding of endometriosis as dysregulations pertain to hormones, hormone receptors, immune function, and transformation to ovarian cancer, endometriosis still remains mysterious from many facets. Critically needed for this enigmatic disease are mechanistic understandings of disease initiation and perturbation that will hopefully lead to the development of noninvasive disease diagnosis and the development of treatments that do not negate hormonal cyclicity or have other undesired side-effect profiles and decrease the need for surgical extirpation. To allow for this to happen, the following areas of need are identified:

  • Establish clear limits to animal models and clarify what the model may and may not reveal.

  • Establish international standards for collection of patient information and samples as outlined by (Fassbender et al. 2013).

  • Establish disease profile through clearer understanding of cytokines and the potential association with autoimmune disorders.

  • Characterization of interplay between the hormonal milieu and immune system.

  • Focus on lifetime exposures, acute and chronic, to endocrine disrupting chemicals that may interfere with uterine development, immune system regulation, and ultimately endometriosis development.

  • Full recognition that this disease is truly multifaceted with pain, psychology, infertility, immunity, etc.

  • Transformation of endometriosis to ovarian cancer through characterization of the lag between endometriosis found on the ovary to an ovarian cancer diagnosis.

  • Determine if age, parity, weight, and hormonal regulators (oral contraceptives) contribute to transformation to cancer diagnosis.

Declaration of Interest

A D G, S A L, J A K, J M S-R, and K A B do not have any conflict of interests to disclose. T J H, in the last 2 years, has served on Advisory boards to: Roche/Genentech, AstraZeneca, Caris Life Sciences, Clovis Oncology, and Johnson & Johnson.

Funding

Funding for this research was provided in part by NIEHS grant 4R00ES021737-02 and Startup Funds from the University of Cincinnati College of Medicine to K A B.

References

  • Abu HashimH2014Potential role of aromatase inhibitors in the treatment of endometriosis. International Journal of Womens Health6671680. (doi:10.2147/IJWH)

    • Search Google Scholar
    • Export Citation
  • AcienPVelascoIAcienMCapelloCVelaP2015Epithelial ovarian cancers and endometriosis. Gynecologic and Obstetric Investigation79126135. (doi:10.1159/issn.0378-7346)

    • Search Google Scholar
    • Export Citation
  • AgarwalSFraserMAChenISinghSS2015Dienogest for the treatment of deep endometriosis: case report and literature review. Journal of Obstetrics and Gynaecology Research41309313. (doi:10.1111/jog.12527)

    • Search Google Scholar
    • Export Citation
  • AhnSMonsantoSMillerCSinghSThomasRTayadeC2015aPathophysiology and immune dysfunction in endometriosis. BioMed Research International2015795976. (doi:10.1155/2015/795976)

    • Search Google Scholar
    • Export Citation
  • AhnSHEdwardsAKSinghSSYoungSLLesseyBATayadeC2015bIL-17A Contributes to the pathogenesis of endometriosis by triggering proinflammatory cytokines and angiogenic growth factors. Journal of Immunology19525912600. (doi:10.4049/jimmunol.1501138)

    • Search Google Scholar
    • Export Citation
  • Akbarzadeh-JahromiMShekarkharGSari AslaniFAzarpiraNHeidari EsfahaniMMomtahanM2015Prevalence of endometriosis in malignant epithelial ovarian tumor. Archieves of Iranian Medicine18844848.

    • Search Google Scholar
    • Export Citation
  • AlmassinokianiFAlmasiAAkbariPSaberifardM2014Effect of Letrozole on endometriosis-related pelvic pain. Medical Journal of the Islamic Republic of Iran28107.

    • Search Google Scholar
    • Export Citation
  • American Society for Reproductive Medicine1997Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertility and Sterility67817821. (doi:10.1016/S0015-0282(97)81391-X)

    • Search Google Scholar
    • Export Citation
  • AndreoliCGGenroVKSouzaCAMichelonTBilibioJPScheffelCCunha-FilhoJS2011T helper (Th)1, Th2, and Th17 interleukin pathways in infertile patients with minimal/mild endometriosis. Fertility and Sterility9524772480. (doi:10.1016/j.fertnstert.2011.02.019)

    • Search Google Scholar
    • Export Citation
  • Andres MdePLopesLABaracatECPodgaecS2015Dienogest in the treatment of endometriosis: systematic review. Archives of Gynecology and Obstetrics292523529. (doi:10.1007/s00404-015-3681-6)

    • Search Google Scholar
    • Export Citation
  • AngioniSCofeliceVPontisATinelliRSocolovR2014New trends of progestins treatment of endometriosis. Gynecological Endocrinology30769773. (doi:10.3109/09513590.2014.950646)

    • Search Google Scholar
    • Export Citation
  • AnglesioMSBashashatiAWangYKSenzJHaGYangWAnibaMRPrenticeLMFarahaniHLi ChangH2015Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. Journal of Pathology236201209. (doi:10.1002/path.2015.236.issue-2)

    • Search Google Scholar
    • Export Citation
  • AokiDKatsukiYShimizuAKakinumaCNozawaS1994Successful heterotransplantation of human endometrium in SCID mice. Obstetrics and Gynecology83220228.

    • Search Google Scholar
    • Export Citation
  • ArisA2010Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada. Journal of Ovarian Research32. (doi:10.1186/1757-2215-3-2)

    • Search Google Scholar
    • Export Citation
  • AyhanAMaoTLSeckinTWuCHGuanBOgawaHFutagamiMMizukamiHYokoyamaYKurmanRJ2012Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. International Journal of Gynecological Cancer2213101315. (doi:10.1097/IGC.0b013e31826b5dcc)

    • Search Google Scholar
    • Export Citation
  • BarczEMilewskiLDziunyczPKaminskiPPloskiRMalejczykJ2012Peritoneal cytokines and adhesion formation in endometriosis: an inverse association with vascular endothelial growth factor concentration. Fertility and Sterility9713801386. (doi:10.1016/j.fertnstert.2012.03.057)

    • Search Google Scholar
    • Export Citation
  • BedaiwyMAPattersonBMahajanS2013Prevalence of myofascial chronic pelvic pain and the effectiveness of pelvic floor physical therapy. Journal of Reproductive Medicine58504510. (doi:10.1016/j.juro.2015.06.065)

    • Search Google Scholar
    • Export Citation
  • BedaiwyMADahoudWSkomorovska-ProkvolitYYiLLiuJHFalconeTHurdWWMesianoS2015Abundance and localization of progesterone receptor isoforms in endometrium in women with and without endometriosis and in peritoneal and ovarian endometriotic implants. Reproductive Sciences2211531161. (doi:10.1177/1933719115585145)

    • Search Google Scholar
    • Export Citation
  • BellelisPBarbeiroDFRizzoLVBaracatECAbraoMSPodgaecS2013Transcriptional changes in the expression of chemokines related to natural killer and T-regulatory cells in patients with deep infiltrative endometriosis. Fertility and Sterility9919871993. (doi:10.1016/j.fertnstert.2013.02.038)

    • Search Google Scholar
    • Export Citation
  • BersingerNADechaudHMcKinnonBMuellerMD2012Analysis of cytokines in the peritoneal fluid of endometriosis patients as a function of the menstrual cycle stage using the Bio-Plex(R) platform. Archives of Physiology and Biochemistry118210218. (doi:10.3109/13813455.2012.687003)

    • Search Google Scholar
    • Export Citation
  • BesteMTPfaffle-DoyleNPrenticeEAMorrisSNLauffenburgerDAIsaacsonKBGriffithLG2014Molecular network analysis of endometriosis reveals a role for c-Jun-regulated macrophage activation. Science Translational Medicine6 222ra16. (doi:10.1126/scitranslmed.3007988)

    • Search Google Scholar
    • Export Citation
  • BonocherCMMontenegroMLRosaESJCFerrianiRAMeolaJ2014Endometriosis and physical exercises: a systematic review. Reproductive Biology and Endocrinology124. (doi:10.1186/1477-7827-12-4)

    • Search Google Scholar
    • Export Citation
  • BourlevVIljasovaNAdamyanLLarssonAOlovssonM2010Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. Fertility and Sterility945257. (doi:10.1016/j.fertnstert.2009.02.019)

    • Search Google Scholar
    • Export Citation
  • BoyrazGSelcukIYaziciogluATuncerZS2013Ovarian carcinoma associated with endometriosis. European Journal of Obstetrics Gynecology and Reproductive Biology170211213. (doi:10.1016/j.ejogrb.2013.06.001)

    • Search Google Scholar
    • Export Citation
  • Braza-BoilsAGilabert-EstellesJRamonLAGilabertJMari-AlexandreJChirivellaMEspanaFEstellesA2013Peritoneal fluid reduces angiogenesis-related microRNA expression in cell cultures of endometrial and endometriotic tissues from women with endometriosis. PLoS ONE8e62370. (doi:10.1371/journal.pone.0062370)

    • Search Google Scholar
    • Export Citation
  • Braza-BoilsAMari-AlexandreJGilabertJSanchez-IzquierdoDEspanaFEstellesAGilabert-EstellesJ2014MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors. Hum Reproduction29978988. (doi:10.1093/humrep/deu019)

    • Search Google Scholar
    • Export Citation
  • Braza-BoilsASalloum-AsfarSMari-AlexandreJArroyoABGonzalez-ConejeroRBarcelo-MolinaMGarcia-OmsJVicenteVEstellesAGilabert-EstellesJ2015Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis. Human Reproduction3022922302. (doi:10.1093/humrep/dev204)

    • Search Google Scholar
    • Export Citation
  • BrintonLAGridleyGPerssonIBaronJBergqvistA1997Cancer risk after a hospital discharge diagnosis of endometriosis. American Journal of Obstetrics and Gynecology176572579. (doi:10.1016/S0002-9378(97)70550-7)

    • Search Google Scholar
    • Export Citation
  • BrintonLASakodaLCShermanMEFrederiksenKKjaerSKGraubardBIOlsenJHMellemkjaerL2005Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiology Biomarkers & Prevention1429292935. (doi:10.1158/1055-9965.EPI-05-0394)

    • Search Google Scholar
    • Export Citation
  • BrownJFarquharC2015An overview of treatments for endometriosis. JAMA313296297. (doi:10.1001/jama.2014.17119)

  • Bruner-TranKMcConahaMOsteenK2012Models of endometriosis: animal models I – rodent-based chimeric models. In Endometriosis: Science and Practice.Chichester, UK: Wiley-Blackwell. (doi:10.1002/9781444398519.ch26)

    • Search Google Scholar
    • Export Citation
  • BukulmezOHardyDBCarrBRWordRAMendelsonCR2008Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology14911901204. (doi:10.1210/en.2007-0665)

    • Search Google Scholar
    • Export Citation
  • BulunSE2009Endometriosis. New England Journal of Medicine360268279. (doi:10.1056/NEJMra0804690)

  • BulunSEMonsavaisDPavoneMEDysonMXueQAttarETokunagaHSuEJ2012Role of estrogen receptor-beta in endometriosis. Seminars in Reproductive Medicine303945. (doi:10.1055/s-0031-1299596)

    • Search Google Scholar
    • Export Citation
  • BulunSEMonsivaisDKakinumaTFurukawaYBernardiLPavoneMEDysonM2015Molecular biology of endometriosis: from aromatase to genomic abnormalities. Seminars in Reproductive Medicine33220224. (doi:10.1055/s-0035-1554053)

    • Search Google Scholar
    • Export Citation
  • BurneyROTalbiSHamiltonAEVoKCNyegaardMNezhatCRLesseyBAGiudiceLC2007Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology14838143826. (doi:10.1210/en.2006-1692)

    • Search Google Scholar
    • Export Citation
  • BurnsKARodriguezKFHewittSCJanardhanKSYoungSLKorachKS2012Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model. Endocrinology15339603971. (doi:10.1210/en.2012-1294)

    • Search Google Scholar
    • Export Citation
  • CarmonaFChapronCMartinez-ZamoraMASantulliPRabanalAMartinez-FlorensaMLozanoFBalaschJ2012Ovarian endometrioma but not deep infiltrating endometriosis is associated with increased serum levels of interleukin-8 and interleukin-6. Journal of Reproductive Immunology958086. (doi:10.1016/j.jri.2012.06.001)

    • Search Google Scholar
    • Export Citation
  • CarrBJOchoaLRankinDOwensBD2009Biologic response to orthopedic sutures: a histologic study in a rabbit model. Orthopedics32828. (doi:10.3928/01477447-20090922-11)

    • Search Google Scholar
    • Export Citation
  • CarrBDmowskiWPO’BrienCJiangPBurkeJJimenezRGarnerEChwaliszK2014Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reproductive Sciences2113411351. (doi:10.1177/1933719114549848)

    • Search Google Scholar
    • Export Citation
  • ChenSQLiJBJiangHYYuanLNiuGYaoSZ2013aExpression of human beta-defensin-2 in the eutopic and ectopic endometrial tissues in patients with endometriosis.Archives of Gynecology and Obstetrics28711511157. (doi:10.1007/s00404-012-2686-7)

    • Search Google Scholar
    • Export Citation
  • ChenYJWuHHLiauWTTsaiCYTsaiHWChaoKCSungYJLiHY2013bA tumor necrosis factor-alpha inhibitor reduces the embryotoxic effects of endometriotic peritoneal fluid. Fertility and Sterility10014761485. (doi:10.1016/j.fertnstert.2013.07.1985)

    • Search Google Scholar
    • Export Citation
  • ChenSWuRFSuLZhouWDZhuMBChenQH2014Lipoxin A4 regulates expression of the estrogen receptor and inhibits 17beta-estradiol induced p38 mitogen-activated protein kinase phosphorylation in human endometriotic stromal cells. Fertility and Sterility102264271. (doi:10.1016/j.fertnstert.2014.03.029)

    • Search Google Scholar
    • Export Citation
  • CheneGOuelletVRahimiKBarresVProvencherDMes-MassonAM2015The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis. International Journal of Gynaecology and Obstetrics1302730. (doi:10.1016/j.ijgo.2015.02.021)

    • Search Google Scholar
    • Export Citation
  • ColetteSDefrereSLousseJCVan LangendoncktAGottelandJPLoumayeEDonnezJ2011Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model. Human Reproduction2613621370. (doi:10.1093/humrep/der079)

    • Search Google Scholar
    • Export Citation
  • CummingsAMetcalfJ1995Induction of endometriosis in mice: a new model sensitive to estrogen. Reproductive Toxicology9233238. (doi:10.1016/0890-6238(95)00004-T)

    • Search Google Scholar
    • Export Citation
  • D’HoogheTBambraCSulemanMDunselmanGEversHKoninckxP1994Development of a model of retrograde menstruation in baboons (Papio anubis). Fertility and Sterility62635638. (doi:10.1016/S0015-0282(16)56957-X)

    • Search Google Scholar
    • Export Citation
  • D’HoogheTBambraCRaeymaekersBDe JongeILauwerynsJKoninckxP1995Intrapelvic injection of menstrual endometrium causes endometriosis in baboons (Papio cynocephalus and Papio anubis). American Journal of Obstetrics and Gynecology173125134. (doi:10.1016/0002-9378(95)90180-9)

    • Search Google Scholar
    • Export Citation
  • D’hoogheTBambraCDe JongeILauwerynsJKoninckxP1996The prevalence of spontaneous endometriosis in the baboon (Papio anubis, Papio cynocephalus) increases with the duration of captivity. Acta Obstetricia et Gynecologica Scandinavica7598101. (doi:10.3109/00016349609033298)

    • Search Google Scholar
    • Export Citation
  • DanielsJPMiddletonLXiongTChampaneriaRJohnsonNPLichtenEMSuttonCVercelliniPGrayRHillsRK2010Individual patient data meta-analysis of randomized evidence to assess the effectiveness of laparoscopic uterosacral nerve ablation in chronic pelvic pain. Human Reproduction Update16568576. (doi:10.1093/humupd/dmq031)

    • Search Google Scholar
    • Export Citation
  • DavisMRauh-HainJAAndradeCBorutaDM 2ndSchorgeJOHorowitzNSMayTdel CarmenMG2014Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecologic Oncology132760766. (doi:10.1016/j.ygyno.2014.01.012)

    • Search Google Scholar
    • Export Citation
  • DelbandiAAMahmoudiMShervinAAkbariEJeddi-TehraniMSankianMKazemnejadSZarnaniAH2013Eutopic and ectopic stromal cells from patients with endometriosis exhibit differential invasive, adhesive, and proliferative behavior. Fertility and Sterility100761769. (doi:10.1016/j.fertnstert.2013.04.041)

    • Search Google Scholar
    • Export Citation
  • DuffyJMArambageKCorreaFJOliveDFarquharCGarryRBarlowDHJacobsonTZ2014Laparoscopic surgery for endometriosis. Cochrane Database of Systematic Reviews4CD011031. (doi:10.1002/14651858.CD011031.pub2)

    • Search Google Scholar
    • Export Citation
  • DunselmanGAVermeulenNBeckerCCalhaz-JorgeCD’HoogheTDe BieBHeikinheimoOHorneAWKieselLNapA2014ESHRE guideline: management of women with endometriosis. Human Reproduction29400412. (doi:10.1093/humrep/det457)

    • Search Google Scholar
    • Export Citation
  • DysonMTRoqueiroDMonsivaisDErcanCMPavoneMEBrooksDCKakinumaTOnoMJafariNDaiYBulunSE2014Genome-wide DNA methylation analysis predicts an epigenetic switch for GATA factor expression in endometriosis. PLoS Genetics10e1004158. (doi:10.1371/journal.pgen.1004158)

    • Search Google Scholar
    • Export Citation
  • Dzatic-SmiljkovicOVasiljevicMDjukicMVugdelicRVugdelicJ2011Frequency of ovarian endometriosis in epithelial ovarian cancer patients. Clinical and Experimental Obstetrics & Gynecology38394398.

    • Search Google Scholar
    • Export Citation
  • ElgaforElSharkwyIA2013Combination of non-invasive and semi-invasive tests for diagnosis of minimal to mild endometriosis. Archives of Gynecology and Obstetrics288793797. (doi:10.1007/s00404-013-2822-z)

    • Search Google Scholar
    • Export Citation
  • EzzatiMCarrBR2015Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health111928. (doi:10.2217/whe.14.68)

    • Search Google Scholar
    • Export Citation
  • FassbenderAVodolazkaiaASaundersPLebovicDWaelkensEDe MoorBD’HoogheT2013Biomarkers of endometriosis. Fertility and Sterility9911351145. (doi:10.1016/j.fertnstert.2013.01.097)

    • Search Google Scholar
    • Export Citation
  • FernandoSSohPQCooperMEvansSReidGTsaltasJRombautsL2013Reliability of visual diagnosis of endometriosis. Journal of Minimally Invasive Gynecology20783789. (doi:10.1016/j.jmig.2013.04.017)

    • Search Google Scholar
    • Export Citation
  • FlowerALiuJPLewithGLittlePLiQ2012Chinese herbal medicine for endometriosis. Cochrane Database of Systematic Review5CD006568. (doi:10.1002/14651858.CD006568.pub3)

    • Search Google Scholar
    • Export Citation
  • FritzMASperoffL2011Clinical Gynecologic Endocrinology and Infertility. Philadelphia, PA, USA: Lippincott Williams and Wilkins.

  • FunamizuAFukuiAKamoiMFuchinoueKYokotaMFukuharaRMizunumaH2014Expression of natural cytotoxicity receptors on peritoneal fluid natural killer cell and cytokine production by peritoneal fluid natural killer cell in women with endometriosis. American Journal of Reproductive Immunology71359367. (doi:10.1111/aji.2014.71.issue-4)

    • Search Google Scholar
    • Export Citation
  • GadducciALanfrediniNTanaR2014Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. Gynecological Endocrinology30612617. (doi:10.3109/09513590.2014.926325)

    • Search Google Scholar
    • Export Citation
  • GalicVColemanRLHerzogTJ2013Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Current Cancer Drug Targets13698707. (doi:10.2174/15680096113139990002)

    • Search Google Scholar
    • Export Citation
  • GoncalvesHFZendronCCavalcanteFSAicelesVOliveiraMAManaiaJHBabinskiMARamosCF2015Leptin, its receptor and aromatase expression in deep infiltrating endometriosis. Journal of Ovarian Research853. (doi:10.1186/s13048-015-0180-0)

    • Search Google Scholar
    • Export Citation
  • GraneseRPerinoACalagnaGSaittaSDe FranciscisPColacurciNTrioloOCucinellaG2015Gonadotrophin-releasing hormone analogue or dienogest plus estradiol valerate to prevent pain recurrence after laparoscopic surgery for endometriosis: a multi-center randomized trial. Acta Obstetricia et Gynecologica Scandinavica94637645. (doi:10.1111/aogs.2015.94.issue-6)

    • Search Google Scholar
    • Export Citation
  • GreavesECousinsFLMurrayAEsnal-ZufiaurreAFassbenderAHorneAWSaundersPT2014A novel mouse model of endometriosis mimics human phenotype and reveals insights into the inflammatory contribution of shed endometrium. American Journal of Pathology18419301939. (doi:10.1016/j.ajpath.2014.03.011)

    • Search Google Scholar
    • Export Citation
  • GreenbergLHSlaydenOD2004Human endometriotic xenografts in immunodeficient RAG-2/gamma(c)KO mice. American Journal of Obstetrics and Gynecology19017881795; discussion 17951786. (doi:10.1016/j.ajog.2004.02.047)

    • Search Google Scholar
    • Export Citation
  • GrummerR2012Models of endometriosis: in vitro and in vivo models. In Endometriosis: Science and Practice.Chichester, UK: Wiley-Blackwell. (doi:10.1002/9781444398519.ch25)

    • Search Google Scholar
    • Export Citation
  • GuoYChenYLiuLBChangKKLiHLiMQShaoJ2013IL-22 in the endometriotic milieu promotes the proliferation of endometrial stromal cells via stimulating the secretion of CCL2 and IL-8. International Journal of Clinical and Experimental Pathology620112020.

    • Search Google Scholar
    • Export Citation
  • HanSJHawkinsSMBegumKJungSYKovanciEQinJLydonJPDeMayoFJO’MalleyBW2012A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis. Nature Medicine1811021111. (doi:10.1038/nm.2826)

    • Search Google Scholar
    • Export Citation
  • HanSJJungSYWuSPHawkinsSMParkMJKyoSQinJLydonJPTsaiSYTsaiMJ2015Estrogen receptor beta modulates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis. Cell163960974. (doi:10.1016/j.cell.2015.10.034)

    • Search Google Scholar
    • Export Citation
  • HansenSOKnudsenUB2013Endometriosis, dysmenorrhoea and diet. European Journal of Obstetrics Gynecology and Reproductive Biology169162171. (doi:10.1016/j.ejogrb.2013.03.028)

    • Search Google Scholar
    • Export Citation
  • HaradaTMomoedaMTaketaniYHoshiaiHTerakawaN2008Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertility and Sterility9015831588. (doi:10.1016/j.fertnstert.2007.08.051)

    • Search Google Scholar
    • Export Citation
  • HealeyMChengCKaurH2014To excise or ablate endometriosis? A prospective randomized double-blinded trial after 5-year follow-up. Journal of Minimally Invasive Gynecology219991004. (doi:10.1016/j.jmig.2014.04.002)

    • Search Google Scholar
    • Export Citation
  • HeringtonJLCrispensMACarvalho-MacedoACCamargosAFLebovicDIBruner-TranKLOsteenKG2011Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. Fertility and Sterility9512951301. (doi:10.1016/j.fertnstert.2010.09.017)

    • Search Google Scholar
    • Export Citation
  • HickeyMBallardKFarquharC2014Endometriosis. BMJ348g1752. (doi:10.1136/bmj.g1752)

  • HsuALKhachikyanIStrattonP2010Invasive and noninvasive methods for the diagnosis of endometriosis. Clinical Obstetrics and Gynecology53413419. (doi:10.1097/GRF.0b013e3181db7ce8)

    • Search Google Scholar
    • Export Citation
  • HuangHNLinMCHuangWCChiangYCKuoKT2014Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Modern Pathology27983990. (doi:10.1038/modpathol.2013.216)

    • Search Google Scholar
    • Export Citation
  • HullMLJohanMZHodgeWLRobertsonSAIngmanWV2012Host-derived TGFB1 deficiency suppresses lesion development in a mouse model of endometriosis. American Journal of Pathology180880887. (doi:10.1016/j.ajpath.2011.11.013)

    • Search Google Scholar
    • Export Citation
  • IladRSFlemingSDMurphyCRFazleabasAT2010Immunohistochemical study of the ubiquitin-nuclear factor-kB pathway in the endometrium of the baboon (Papio anubis) with and without endometriosis. Reproduction Fertility and Development2211181130. (doi:10.1071/RD08086)

    • Search Google Scholar
    • Export Citation
  • ImaiAMatsunamiKTakagiHIchigoS2014Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review. Clinical and Experimental Obstetrics & Gynecology41495498. (doi:10.12891/ceog17042014)

    • Search Google Scholar
    • Export Citation
  • Juhasz-BossIHofeleALattrichCBuchholzSOrtmannOMalikE2010Matrix metalloproteinase messenger RNA expression in human endometriosis grafts cultured on a chicken chorioallantoic membrane. Fertility and Sterility944045. (doi:10.1016/j.fertnstert.2009.02.052)

    • Search Google Scholar
    • Export Citation
  • KangYJJeungICParkAParkYJJungHKimTDLeeHGChoiIYoonSR2014An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression. Human Reproduction2921762189. (doi:10.1093/humrep/deu172)

    • Search Google Scholar
    • Export Citation
  • KeitaMBessettePPelmusMAinmelkYArisA2010Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes. Journal of Ovarian Research33. (doi:10.1186/1757-2215-3-3)

    • Search Google Scholar
    • Export Citation
  • KeitaMAinMelkYPelmusMBessettePArisA2011Endometrioid ovarian cancer and endometriotic cells exhibit the same alteration in the expression of interleukin-1 receptor II: to a link between endometriosis and endometrioid ovarian cancer. Journal of Obstetrics and Gynaecology Research3799107. (doi:10.1111/jog.2011.37.issue-2)

    • Search Google Scholar
    • Export Citation
  • KhanKNKitajimaMInoueTFujishitaANakashimaMMasuzakiH201517beta-estradiol and lipopolysaccharide additively promote pelvic inflammation and growth of endometriosis. Reproductive Sciences22585594. (doi:10.1177/1933719114556487)

    • Search Google Scholar
    • Export Citation
  • KimHSKimTHChungHHSongYS2014Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. British Journal of Cancer11018781890. (doi:10.1038/bjc.2014.29)

    • Search Google Scholar
    • Export Citation
  • KingCBarbaraCPrenticeABrentonJCharnock-JonesD2016Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma. Journal of Pathology238185196. (doi:10.1002/path.4657)

    • Search Google Scholar
    • Export Citation
  • KinugasaSShinoharaKWakatsukiA2011Increased asymmetric dimethylarginine and enhanced inflammation are associated with impaired vascular reactivity in women with endometriosis. Atherosclerosis219784788. (doi:10.1016/j.atherosclerosis.2011.08.005)

    • Search Google Scholar
    • Export Citation
  • KobayashiHYamadaYKanayamaSFurukawaNNoguchiTHarutaSYoshidaSSakataMSadoTOiH2009The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. International Journal of Gynecological Cancer19471479. (doi:10.1111/IGC.0b013e3181a19eca)

    • Search Google Scholar
    • Export Citation
  • Kondi-PafitiAPapakonstantinouEIavazzoCGrigoriadisCSalakosNGregoriouO2012Clinicopathological characteristics of ovarian carcinomas associated with endometriosis. Archives of Gynecology and Obstetrics285479483. (doi:10.1007/s00404-011-1957-z)

    • Search Google Scholar
    • Export Citation
  • KongSZhangYHLiuCFTsuiIGuoYAiBBHanFJ2014The complementary and alternative medicine for endometriosis: a review of utilization and mechanism. Evidence-Based Complementary and Alternative Medicine2014 146383. (doi:10.1155/2014/146383)

    • Search Google Scholar
    • Export Citation
  • KulakJJrFischerCKommBTaylorHS2011Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology15232263232. (doi:10.1210/en.2010-1010)

    • Search Google Scholar
    • Export Citation
  • KumarSMunkarahAArabiHBandyopadhyaySSemaanAHayekKGargGMorrisRAli-FehmiR2011Prognostic analysis of ovarian cancer associated with endometriosis. American Journal of Obstetrics and Gynecology20463.e163.e7. (doi:10.1016/j.ajog.2010.08.017)

    • Search Google Scholar
    • Export Citation
  • KumarRClercACGoriIRussellRPellegriniCGovenderLWyssJCGolshayanDCannyGO2014Lipoxin A(4) prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E(2) production and estrogen signaling. PLoS ONE9e89742. (doi:10.1371/journal.pone.0089742)

    • Search Google Scholar
    • Export Citation
  • LaiCRHsuCYChenYJYenMSChaoKCLiAF2013Ovarian cancers arising from endometriosis: a microenvironmental biomarker study including ER, HNF1ss, p53, PTEN, BAF250a, and COX-2. Journal of the Chinese Medical Association76629634. (doi:10.1016/j.jcma.2013.07.008)

    • Search Google Scholar
    • Export Citation
  • LebovicDIKavoussiSKLeeJBanuSKAroshJA2013PPARgamma activation inhibits growth and survival of human endometriotic cells by suppressing estrogen biosynthesis and PGE2 signaling. Endocrinology15448034813. (doi:10.1210/en.2013-1168)

    • Search Google Scholar
    • Export Citation
  • LeconteMChouzenouxSNiccoCChereauCArkwrightSSantulliPWeillBChapronCDoussetBBatteuxF2014Role of the CXCL12-CXCR4 axis in the development of deep rectal endometriosis. Journal of Reproductive Immunology1034552. (doi:10.1016/j.jri.2013.12.121)

    • Search Google Scholar
    • Export Citation
  • LeeDHKimSCJooJKKimHGNaYJKwakJYLeeKS2012Effects of 17beta-estradiol on the release of monocyte chemotactic protein-1 and MAPK activity in monocytes stimulated with peritoneal fluid from endometriosis patients. Journal of Obstetrics and Gynaecology Research38516525. (doi:10.1111/jog.2012.38.issue-3)

    • Search Google Scholar
    • Export Citation
  • LeeAWTemplemanCStramDABeesleyJTyrerJBerchuckAPharoahPPChenevix-TrenchGPearceCLOvarian Cancer Association C2016Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility1053543 e10. (doi:10.1016/j.fertnstert.2015.09.023)

    • Search Google Scholar
    • Export Citation
  • Leone Roberti MaggioreUScalaCRemorgidaVVenturiniPLDel DeoFTorellaMColacurciNSalvatoreSFerrariSPapaleoE2014Triptorelin for the treatment of endometriosis. Expert Opinion on Pharmacotherapy1511531179. (doi:10.1517/14656566.2014.916279)

    • Search Google Scholar
    • Export Citation
  • LinWChenSLiMWangBQuXZhangY2010Expression of macrophage migration inhibitory factor in human endometriosis: relation to disease stage, menstrual cycle and infertility. Journal of Obstetrics and Gynaecology Research36344351. (doi:10.1111/(ISSN)1447-0756)

    • Search Google Scholar
    • Export Citation
  • LoweryWJSchildkrautJMAkushevichLBentleyRMarksJRHuntsmanDBerchuckA2012Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. International Journal of Gynecological Cancer22914. (doi:10.1097/IGC.0b013e318231f140)

    • Search Google Scholar
    • Export Citation
  • LuZZhangWJiangSZouJLiY2014aEffect of lesion location on endometriotic adhesion and angiogenesis in SCID mice.Archives of Gynecology and Obstetrics289823830. (doi:10.1007/s00404-013-3048-9)

    • Search Google Scholar
    • Export Citation
  • LuZZhangWJiangSZouJLiY2014bEffect of oxygen tensions on the proliferation and angiogenesis of endometriosis heterograft in severe combined immunodeficiency mice.Fertility and Sterility101568576. (doi:10.1016/j.fertnstert.2013.10.039)

    • Search Google Scholar
    • Export Citation
  • LukJSevalYUlukusMUlukusECAriciAKayisliUA2010Regulation of monocyte chemotactic protein-1 expression in human endometrial endothelial cells by sex steroids: a potential mechanism for leukocyte recruitment in endometriosis. Reproductive Sciences17278287. (doi:10.1177/1933719109352380)

    • Search Google Scholar
    • Export Citation
  • MaasJGroothuisPDunselmanGde GoeijAStruijker-BoudierHEversJ2001Development of endometriosis-like lesions after transplantation of human endometrial fragments onto the chick embryo chorioallantoic membrane. Human Reproduction16627631. (doi:10.1093/humrep/16.4.627)

    • Search Google Scholar
    • Export Citation
  • MachadoDEBerardoPTPalmeroCYNasciuttiLE2010Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. Journal of Experimental & Clinical Cancer Research294. (doi:10.1186/1756-9966-29-4)

    • Search Google Scholar
    • Export Citation
  • MachadoDEPalumboAJrSantosJMMattosRMdos SantosTASeabraSHPeriniJANasciuttiLE2014A GFP endometriosis model reveals important morphological characteristics of the angiogenic process that govern benign and malignant diseases.Histology and Histopathology29903912. (doi:10.14670/HH-29.903)

    • Search Google Scholar
    • Export Citation
  • MalhotraNKarmakarDTripathiVLuthraKKumarS2012Correlation of angiogenic cytokines-leptin and IL-8 in stage, type and presentation of endometriosis. Gynecological Endocrinology28224227. (doi:10.3109/09513590.2011.593664)

    • Search Google Scholar
    • Export Citation
  • MargariKMZafiropoulosAHatzidakiEGiannakopoulouCAriciAMatalliotakisI2013Peritoneal fluid concentrations of beta-chemokines in endometriosis. European Journal of Obstetrics Gynecology and Reproductive biology169103107. (doi:10.1016/j.ejogrb.2013.02.010)

    • Search Google Scholar
    • Export Citation
  • MatsumotoTYamazakiMTakahashiHKajitaSSuzukiETsurutaTSaegusaM2015Distinct beta-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas. American Journal of Clinical Pathology144452463. (doi:10.1309/AJCPZ5T2POOFMQVN)

    • Search Google Scholar
    • Export Citation
  • McConechyMKDingJSenzJYangWMelnykNToneAAPrenticeLMWiegandKCMcAlpineJNShahSP2014Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Modern Pathology27128134. (doi:10.1038/modpathol.2013.107)

    • Search Google Scholar
    • Export Citation
  • Mier-CabreraJJimenez-ZamudioLGarcia-LatorreECruz-OrozcoOHernandez-GuerreroC2011Quantitative and qualitative peritoneal immune profiles, T-cell apoptosis and oxidative stress-associated characteristics in women with minimal and mild endometriosis. British Journal of Obstetrics & Gynaecology118616. (doi:10.1111/j.1471-0528.2010.02777.x)

    • Search Google Scholar
    • Export Citation
  • MilewskiLDziunyczPBarczERadomskiDRoszkowskiPIKorczak-KowalskaGKaminskiPMalejczykJ2011Increased levels of human neutrophil peptides 1, 2, and 3 in peritoneal fluid of patients with endometriosis: association with neutrophils, T cells and IL-8. Journal of Reproductive Immunology916470. (doi:10.1016/j.jri.2011.05.008)

    • Search Google Scholar
    • Export Citation
  • MonsivaisDDysonMTYinPCoonJSNavarroAFengGMalpaniSSOnoMErcanCMWeiJJ2014ERbeta- and prostaglandin E2-regulated pathways integrate cell proliferation via Ras-like and estrogen-regulated growth inhibitor in endometriosis. Molecular Endocrinology2813041315. (doi:10.1210/me.2013-1421)

    • Search Google Scholar
    • Export Citation
  • MunksgaardPSBlaakaerJ2012The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecologic Oncology124164169. (doi:10.1016/j.ygyno.2011.10.001)

    • Search Google Scholar
    • Export Citation
  • Munoz-HernandoLMunoz-GonzalezJLMarqueta-MarquesLAlvarez-ConejoCTejerizo-GarciaALopez-GonzalezGVillegas-MunozEMartin-JimenezAJimenez-LopezJS2015Endometriosis: alternative methods of medical treatment. International Journal of Womens Health7595603. (doi:10.2147/IJWH.S78829)

    • Search Google Scholar
    • Export Citation
  • MuziiLDi TucciCAchilliCDi DonatoVMusellaAPalaiaIPaniciPB2016Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology214203211. (doi:10.1016/j.ajog.2015.08.074)

    • Search Google Scholar
    • Export Citation
  • NapAWDunselmanGAde GoeijAFEversJLGroothuisPG2004Inhibiting MMP activity prevents the development of endometriosis in the chicken chorioallantoic membrane model. Human Reproduction1921802187. (doi:10.1093/humrep/deh408)

    • Search Google Scholar
    • Export Citation
  • NapAWDunselmanGAGriffioenAWMayoKHEversJLGroothuisPG2005Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertility and Sterility83793795. (doi:10.1016/j.fertnstert.2004.06.080)

    • Search Google Scholar
    • Export Citation
  • NaqviHSakrSPrestiTKrikunGKommBTaylorHS2014Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model. Biology of Reproduction90121. (doi:10.1095/biolreprod.113.114165)

    • Search Google Scholar
    • Export Citation
  • NessRB2003Endometriosis and ovarian cancer: thoughts on shared pathophysiology. American Journal of Obstetrics and Gynecology189280294. (doi:10.1067/mob.2003.408)

    • Search Google Scholar
    • Export Citation
  • NezhatFDattaMSHansonVPejovicTNezhatCNezhatC2008The relationship of endometriosis and ovarian malignancy: a review. Fertility and Sterility9015591570. (doi:10.1016/j.fertnstert.2008.08.007)

    • Search Google Scholar
    • Export Citation
  • Novella-MaestreEHerraizSVila-VivesJMCardaCRuiz-SauriAPellicerA2012Effect of antiangiogenic treatment on peritoneal endometriosis-associated nerve fibers. Fertility and Sterility9812091217. (doi:10.1016/j.fertnstert.2012.07.1103)

    • Search Google Scholar
    • Export Citation
  • Page-McCawAEwaldAJWerbZ2007Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews. Molecular Cell Biology8221233. (doi:10.1038/nrm2125)

    • Search Google Scholar
    • Export Citation
  • PalmerSSAltanMDenisDTosEGGottelandJPOsteenKGBruner-TranKLNatarajaSG2016Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models. Reproductive Sciences231123. (doi:10.1177/1933719115600553)

    • Search Google Scholar
    • Export Citation
  • PearceCLTemplemanCRossingMALeeANearAMWebbPMNagleCMDohertyJACushing-HaugenKLWicklundKG2012Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncology13385394. (doi:10.1016/S1470-2045(11)70404-1)

    • Search Google Scholar
    • Export Citation
  • PellegriniCGoriIAchtariCHornungDChardonnensEWunderDFicheMCannyGO2012The expression of estrogen receptors as well as GREB1, c-MYC, and cyclin D1, estrogen-regulated genes implicated in proliferation, is increased in peritoneal endometriosis. Fertility and Sterility9812001208. (doi:10.1016/j.fertnstert.2012.06.056)

    • Search Google Scholar
    • Export Citation
  • PodgaecSRizzoLVFernandesLFBaracatECAbraoMS2012CD4(+) CD25(high) Foxp3(+) cells increased in the peritoneal fluid of patients with endometriosis. American Journal of Reproductive Immunology68301308. (doi:10.1111/aji.2012.68.issue-4)

    • Search Google Scholar
    • Export Citation
  • PosadzkaEJachRPitynskiKJablonskiMJ2015Treatment efficacy for pain complaints in women with endometriosis of the lesser pelvis after laparoscopic electroablation vs. CO2 laser ablation. Lasers in Medical Science30147152. (doi:10.1007/s10103-014-1630-4)

    • Search Google Scholar
    • Export Citation
  • Practice Committee of the American Society for Reproductive M2014Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertility and Sterility101927935. (doi:10.1016/j.fertnstert.2014.02.012)

    • Search Google Scholar
    • Export Citation
  • RathoreNKriplaniAYadavRKJaiswalUNetamR2014Distinct peritoneal fluid ghrelin and leptin in infertile women with endometriosis and their correlation with interleukin-6 and vascular endothelial growth factor. Gynecological Endocrinology30671675. (doi:10.3109/09513590.2014.920318)

    • Search Google Scholar
    • Export Citation
  • RicciAGOlivaresCNBilotasMAMeresmanGFBaranaoRI2011Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reproductive Sciences18614622. (doi:10.1177/1933719110395406)

    • Search Google Scholar
    • Export Citation
  • RossingMACushing-HaugenKLWicklundKGDohertyJAWeissNS2008Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control1913571364. (doi:10.1007/s10552-008-9207-9)

    • Search Google Scholar
    • Export Citation
  • Rubi-KleinKKucera-SliutzENisselHBijakMStockenhuberDFinkMWolkensteinE2010Is acupuncture in addition to conventional medicine effective as pain treatment for endometriosis? A randomised controlled cross-over trial. European Journal of Obstetrics Gynecology and Reproductive Biology1539093. (doi:10.1016/j.ejogrb.2010.06.023)

    • Search Google Scholar
    • Export Citation
  • RuizASalvoVARuizLABaezPGarciaMFloresI2010Basal and steroid hormone-regulated expression of CXCR4 in human endometrium and endometriosis. Reproductive Sciences17894903. (doi:10.1177/1933719110379920)

    • Search Google Scholar
    • Export Citation
  • SabbaghiMAramRRoustaeiHFadavi IslamMDaneshvarMCastanoARHaghparastA2014IL-17A concentration of seminal plasma and follicular fluid in infertile men and women with various clinical diagnoses. Immunological Investigations43617626. (doi:10.3109/08820139.2014.909453)

    • Search Google Scholar
    • Export Citation
  • SamartzisEPSamartzisNNoskeAFedierACaduffRDedesKJFinkDImeschP2012Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?Modern Pathology25885892. (doi:10.1038/modpathol.2011.217)

    • Search Google Scholar
    • Export Citation
  • SampsonJA1925Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Archives of Surgery10172. (doi:10.1001/archsurg.1925.01120100007001)

    • Search Google Scholar
    • Export Citation
  • SampsonJ1927aMetastatic or Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial Tissue into the Venous Circulation.American Journal of Pathology393110.143.

    • Search Google Scholar
    • Export Citation
  • SampsonJ1927bPeritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity.American Journal of Obstetrics and Gynecology14422469.

    • Search Google Scholar
    • Export Citation
  • SantulliPBorgheseBChouzenouxSStreuliIBorderieDde ZieglerDWeillBChapronCBatteuxF2013Interleukin-19 and interleukin-22 serum levels are decreased in patients with ovarian endometrioma. Fertility and Sterility99219226. (doi:10.1016/j.fertnstert.2012.08.055)

    • Search Google Scholar
    • Export Citation
  • ScarfoneGBergaminiANoliSVillaACiprianiSTaccagniGViganoPCandianiMParazziniFMangiliG2014Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study. Gynecologic Oncology133480484. (doi:10.1016/j.ygyno.2014.03.017)

    • Search Google Scholar
    • Export Citation
  • SchorgeJOModesittSCColemanRLCohnDEKauffNDDuskaLRHerzogTJ2010SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecologic Oncology119717. (doi:10.1016/j.ygyno.2010.06.003)

    • Search Google Scholar
    • Export Citation
  • ScottRB1953Malignant changes in endometriosis. Obstetrics and Gynecology2283289.

  • ScottRTe LindeRWhartonL1953Further studies on experimental endometriosis. American Journal of Obstetrics and Gynecology6610821103.

  • SikoraJMielczarek-PalaczAKondera-AnaszZ2012Imbalance in cytokines from interleukin-1 family – role in pathogenesis of endometriosis. American Journal of Reproductive Immunology68138145. (doi:10.1111/aji.2012.68.issue-2)

    • Search Google Scholar
    • Export Citation
  • SillemMHahnUCoddingtonCGordonKRunnebaumBHodgenG1996Ectopic growth of endometrium depends on its structural integrity and proteolytic activity in the cynomolgus monkey (Macaca fascicularis) model of endometriosis. Fertility and Sterility66468473. (doi:10.1016/S0015-0282(16)58521-5)

    • Search Google Scholar
    • Export Citation
  • SomiglianaEViganoPRossiGCarinelliSVignaliMPanina-BordignonP1999Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Human Reproduction1429442950. (doi:10.1093/humrep/14.12.2944)

    • Search Google Scholar
    • Export Citation
  • StrowitzkiTFaustmannTGerlingerCSchumacherUAhlersCSeitzC2015Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. International Journal of Womens Health7393401. (doi:10.2147/IJWH.S77202)

    • Search Google Scholar
    • Export Citation
  • StyerAKSullivanBTPuderMArsenaultDPetrozzaJCSerikawaTChangSHasanTGonzalezRRRuedaBR2008Ablation of leptin signaling disrupts the establishment, development, and maintenance of endometriosis-like lesions in a murine model. Endocrinology149506514. (doi:10.1210/en.2007-1225)

    • Search Google Scholar
    • Export Citation
  • SuganumaIMoriTItoFTanakaYSasakiAMatsuoSKusukiIKitawakiJ2014Peroxisome proliferator-activated receptor gamma, coactivator 1alpha enhances local estrogen biosynthesis by stimulating aromatase activity in endometriosis.Journal of Clinical Endocrinology and Metabolism99E11911198. (doi:10.1210/jc.2013-2525)

    • Search Google Scholar
    • Export Citation
  • SyropCHHalmeJ1987Peritoneal fluid environment and infertility. Fertility and Sterility4819. (doi:10.1016/S0015-0282(16)59280-2)

  • SzubertMSuzinJDuechlerMSzulawskaACzyzMKowalczyk-AmicoK2014Evaluation of selected angiogenic and inflammatory markers in endometriosis before and after danazol treatment. Reproduction Fertility and Development26414420. (doi:10.1071/RD12258)

    • Search Google Scholar
    • Export Citation
  • TanmahasamutPRattanachaiyanontMAngsuwathanaSTechatraisakKIndhavivadhanaSLeerasiriP2012Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstetrics and Gynecology119519526. (doi:10.1097/AOG.0b013e31824264c3)

    • Search Google Scholar
    • Export Citation
  • TaoYZhangQHuangWZhuHZhangDLuoW2011The peritoneal leptin, MCP-1 and TNF-alpha in the pathogenesis of endometriosis-associated infertility. American Journal of Reproductive Immunology65403406. (doi:10.1111/j.1600-0897.2010.00920.x)

    • Search Google Scholar
    • Export Citation
  • Te LindeRScottR1950Experimental endometriosis. American Journal of Obstetrics and Gynecology6011471173. (doi:10.1016/0002-9378(50)90517-5)

    • Search Google Scholar
    • Export Citation
  • Tirado-GonzalezIBarrientosGTariverdianNArckPGarciaMKlappBBloisS2010Endometriosis research: animal models for the study of a complex disease. Journal of Reproductive Immunology86141147. (doi:10.1016/j.jri.2010.05.001)

    • Search Google Scholar
    • Export Citation
  • VeillatVSengersVMetzCNRogerTLeboeufMMaillouxJAkoumA2012Macrophage migration inhibitory factor is involved in a positive feedback loop increasing aromatase expression in endometriosis. American Journal of Pathology181917927. (doi:10.1016/j.ajpath.2012.05.018)

    • Search Google Scholar
    • Export Citation
  • VelascoIAcienPCamposAAcienMIRuiz-MaciaE2010Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression. Journal of Reproductive Immunology84199205. (doi:10.1016/j.jri.2009.11.004)

    • Search Google Scholar
    • Export Citation
  • VernonMWilsonE1985Studies on the surgical induction of endometriosis in the rat. Fertility and Sterility44684694. (doi:10.1016/S0015-0282(16)48988-0)

    • Search Google Scholar
    • Export Citation
  • ViraniSEdwardsAKThomasRChildsTTayadeC2013Blocking of stromal cell-derived factor-1 reduces neoangiogenesis in human endometriosis lesions in a mouse model. American Journal of Reproductive Immunology70386397. (doi:10.1111/aji.12134)

    • Search Google Scholar
    • Export Citation
  • WangXQYuJLuoXZShiYLWangYWangLLiDJ2010The high level of RANTES in the ectopic milieu recruits macrophages and induces their tolerance in progression of endometriosis. Journal of Molecular Endocrinology45291299. (doi:10.1677/JME-09-0177)

    • Search Google Scholar
    • Export Citation
  • WeiJJWilliamJBulunS2011Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. International Journal of Gynecological Pathology30553568. (doi:10.1097/PGP.0b013e31821f4b85)

    • Search Google Scholar
    • Export Citation
  • WengQDingZMLvXLYangDXSongYZWangFFYeYHQuF2015Chinese medicinal plants for advanced endometriosis after conservative surgery: a prospective, multi-center and controlled trial. International Journal of Clinical and Experimental Medicine81130711311.

    • Search Google Scholar
    • Export Citation
  • WickiewiczDChrobakAGmyrekGBHalbersztadtAGabrysMSGoludaMChelmonska-SoytaA2013Diagnostic accuracy of interleukin-6 levels in peritoneal fluid for detection of endometriosis. Archives of Gynecology and Obstetrics288805814. (doi:10.1007/s00404-013-2828-6)

    • Search Google Scholar
    • Export Citation
  • WiegandKCShahSPAl-AghaOMZhaoYTseKZengTSenzJMcConechyMKAnglesioMSKallogerSE2010ARID1A mutations in endometriosis-associated ovarian carcinomas. New England Journal of Medicine36315321543. (doi:10.1056/NEJMoa1008433)

    • Search Google Scholar
    • Export Citation
  • WiegandKCLeeAFAl-AghaOMChowCKallogerSEScottDWSteidlCWisemanSMGascoyneRDGilksB2011Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. Journal of Pathology224328333. (doi:10.1002/path.v224.3)

    • Search Google Scholar
    • Export Citation
  • WorleyMJJrLiuSHuaYKwokJSSamuelAHouLShoniMLuSSandbergEMKeryanA2015Molecular changes in endometriosis-associated ovarian clear cell carcinoma. European Journal of Cancer5118311842. (doi:10.1016/j.ejca.2015.05.011)

    • Search Google Scholar
    • Export Citation
  • WuMHLuCWChangFMTsaiSJ2012Estrogen receptor expression affected by hypoxia inducible factor-1alpha in stromal cells from patients with endometriosis. Taiwanese Journal of Obstetrics & Gynecology515054. (doi:10.1016/j.tjog.2012.01.010)

    • Search Google Scholar
    • Export Citation
  • XuHBeckerCMLuiWTChuCYDavisTNKungALBirsnerAED’AmatoRJWai ManGCWangCC2011Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo. Fertility and Sterility9610211028. (doi:10.1016/j.fertnstert.2011.07.008)

    • Search Google Scholar
    • Export Citation
  • XuHZhangTManGCMayKEBeckerCMDavisTNKungALBirsnerAED’AmatoRJWongAW2013Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis16541551. (doi:10.1007/s10456-013-9333-1)

    • Search Google Scholar
    • Export Citation
  • YangYZhangXZhouCHuangXLinJXuH2013Elevated immunoreactivity of RANTES and CCR1 correlate with the severity of stages and dysmenorrhea in women with deep infiltrating endometriosis. Acta Histochemica115434439. (doi:10.1016/j.acthis.2012.10.006)

    • Search Google Scholar
    • Export Citation
  • YeoSGWonYSLeeHYKimYILeeJWParkDC2013Increased expression of pattern recognition receptors and nitric oxide synthase in patients with endometriosis. International Journal of Medical Sciences1011991208. (doi:10.7150/ijms.5169)

    • Search Google Scholar
    • Export Citation
  • YoungVJBrownJKMaybinJSaundersPTDuncanWCHorneAW2014aTransforming growth factor-beta induced Warburg-like metabolic reprogramming may underpin the development of peritoneal endometriosis.Journal of Clinical Endocrinology and Metabolism9934503459. (doi:10.1210/jc.2014-1026)

    • Search Google Scholar
    • Export Citation
  • YoungVJBrownJKSaundersPTDuncanWCHorneAW2014bThe peritoneum is both a source and target of TGF-beta in women with endometriosis.PLoS ONEe106773. (doi:10.1371/journal.pone.0106773)

    • Search Google Scholar
    • Export Citation
  • ZamahNDodsonMStephensLButtramVBeschPKaufmanR1984Transplantation of normal and ectopic human endometrial tissue into athymic nude mice. American Journal of Obstetrics and Gynecology149591597. (doi:10.1016/0002-9378(84)90240-0)

    • Search Google Scholar
    • Export Citation
  • ZanettaGMWebbMJLiHKeeneyGL2000Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. Gynecologic Oncology791822. (doi:10.1006/gyno.2000.5905)

    • Search Google Scholar
    • Export Citation
  • ZhaoYGongPChenYNwachukwuJCSrinivasanSKoCBagchiMKTaylorRNKorachKSNettlesKWKatzenellenbogenJAKatzenellenbogenBS2015Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. Science Translational Medicine7271ra279. (doi:10.1126/scitranslmed.3010626)

    • Search Google Scholar
    • Export Citation
  • ZitoGLuppiSGioloEMartinelliMVenturinIDi LorenzoGRicciG2014Medical treatments for endometriosis-associated pelvic pain. BioMed Research International2014 191967. (doi:10.1155/2014/191967)

    • Search Google Scholar
    • Export Citation
  • ZondervanKWeeksDColmanRCardonLHadfieldRSchlefflerJGoudy TrainorACoeCKemnitzJKennedyS2004Familial aggregation of endometriosis in a large pedigree of rhesus macaques. Human Reproduction19448455. (doi:10.1093/humrep/deh052)

    • Search Google Scholar
    • Export Citation
  • ZorbasKAEconomopoulosKPVlahosNF2015Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Archives of Gynecology and Obstetrics2923743. (doi:10.1007/s00404-015-3641-1)

    • Search Google Scholar
    • Export Citation

If the inline PDF is not rendering correctly, you can download the PDF file here.

 

    Society for Reproduction and Fertility

Related Articles

Article Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1132 1087 64
PDF Downloads 372 364 24

Altmetrics

References

  • Abu HashimH2014Potential role of aromatase inhibitors in the treatment of endometriosis. International Journal of Womens Health6671680. (doi:10.2147/IJWH)

    • Search Google Scholar
    • Export Citation
  • AcienPVelascoIAcienMCapelloCVelaP2015Epithelial ovarian cancers and endometriosis. Gynecologic and Obstetric Investigation79126135. (doi:10.1159/issn.0378-7346)

    • Search Google Scholar
    • Export Citation
  • AgarwalSFraserMAChenISinghSS2015Dienogest for the treatment of deep endometriosis: case report and literature review. Journal of Obstetrics and Gynaecology Research41309313. (doi:10.1111/jog.12527)

    • Search Google Scholar
    • Export Citation
  • AhnSMonsantoSMillerCSinghSThomasRTayadeC2015aPathophysiology and immune dysfunction in endometriosis. BioMed Research International2015795976. (doi:10.1155/2015/795976)

    • Search Google Scholar
    • Export Citation
  • AhnSHEdwardsAKSinghSSYoungSLLesseyBATayadeC2015bIL-17A Contributes to the pathogenesis of endometriosis by triggering proinflammatory cytokines and angiogenic growth factors. Journal of Immunology19525912600. (doi:10.4049/jimmunol.1501138)

    • Search Google Scholar
    • Export Citation
  • Akbarzadeh-JahromiMShekarkharGSari AslaniFAzarpiraNHeidari EsfahaniMMomtahanM2015Prevalence of endometriosis in malignant epithelial ovarian tumor. Archieves of Iranian Medicine18844848.

    • Search Google Scholar
    • Export Citation
  • AlmassinokianiFAlmasiAAkbariPSaberifardM2014Effect of Letrozole on endometriosis-related pelvic pain. Medical Journal of the Islamic Republic of Iran28107.

    • Search Google Scholar
    • Export Citation
  • American Society for Reproductive Medicine1997Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertility and Sterility67817821. (doi:10.1016/S0015-0282(97)81391-X)

    • Search Google Scholar
    • Export Citation
  • AndreoliCGGenroVKSouzaCAMichelonTBilibioJPScheffelCCunha-FilhoJS2011T helper (Th)1, Th2, and Th17 interleukin pathways in infertile patients with minimal/mild endometriosis. Fertility and Sterility9524772480. (doi:10.1016/j.fertnstert.2011.02.019)

    • Search Google Scholar
    • Export Citation
  • Andres MdePLopesLABaracatECPodgaecS2015Dienogest in the treatment of endometriosis: systematic review. Archives of Gynecology and Obstetrics292523529. (doi:10.1007/s00404-015-3681-6)

    • Search Google Scholar
    • Export Citation
  • AngioniSCofeliceVPontisATinelliRSocolovR2014New trends of progestins treatment of endometriosis. Gynecological Endocrinology30769773. (doi:10.3109/09513590.2014.950646)

    • Search Google Scholar
    • Export Citation
  • AnglesioMSBashashatiAWangYKSenzJHaGYangWAnibaMRPrenticeLMFarahaniHLi ChangH2015Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. Journal of Pathology236201209. (doi:10.1002/path.2015.236.issue-2)

    • Search Google Scholar
    • Export Citation
  • AokiDKatsukiYShimizuAKakinumaCNozawaS1994Successful heterotransplantation of human endometrium in SCID mice. Obstetrics and Gynecology83220228.

    • Search Google Scholar
    • Export Citation
  • ArisA2010Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada. Journal of Ovarian Research32. (doi:10.1186/1757-2215-3-2)

    • Search Google Scholar
    • Export Citation
  • AyhanAMaoTLSeckinTWuCHGuanBOgawaHFutagamiMMizukamiHYokoyamaYKurmanRJ2012Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. International Journal of Gynecological Cancer2213101315. (doi:10.1097/IGC.0b013e31826b5dcc)

    • Search Google Scholar
    • Export Citation
  • BarczEMilewskiLDziunyczPKaminskiPPloskiRMalejczykJ2012Peritoneal cytokines and adhesion formation in endometriosis: an inverse association with vascular endothelial growth factor concentration. Fertility and Sterility9713801386. (doi:10.1016/j.fertnstert.2012.03.057)

    • Search Google Scholar
    • Export Citation
  • BedaiwyMAPattersonBMahajanS2013Prevalence of myofascial chronic pelvic pain and the effectiveness of pelvic floor physical therapy. Journal of Reproductive Medicine58504510. (doi:10.1016/j.juro.2015.06.065)

    • Search Google Scholar
    • Export Citation
  • BedaiwyMADahoudWSkomorovska-ProkvolitYYiLLiuJHFalconeTHurdWWMesianoS2015Abundance and localization of progesterone receptor isoforms in endometrium in women with and without endometriosis and in peritoneal and ovarian endometriotic implants. Reproductive Sciences2211531161. (doi:10.1177/1933719115585145)

    • Search Google Scholar
    • Export Citation
  • BellelisPBarbeiroDFRizzoLVBaracatECAbraoMSPodgaecS2013Transcriptional changes in the expression of chemokines related to natural killer and T-regulatory cells in patients with deep infiltrative endometriosis. Fertility and Sterility9919871993. (doi:10.1016/j.fertnstert.2013.02.038)

    • Search Google Scholar
    • Export Citation
  • BersingerNADechaudHMcKinnonBMuellerMD2012Analysis of cytokines in the peritoneal fluid of endometriosis patients as a function of the menstrual cycle stage using the Bio-Plex(R) platform. Archives of Physiology and Biochemistry118210218. (doi:10.3109/13813455.2012.687003)

    • Search Google Scholar
    • Export Citation
  • BesteMTPfaffle-DoyleNPrenticeEAMorrisSNLauffenburgerDAIsaacsonKBGriffithLG2014Molecular network analysis of endometriosis reveals a role for c-Jun-regulated macrophage activation. Science Translational Medicine6 222ra16. (doi:10.1126/scitranslmed.3007988)

    • Search Google Scholar
    • Export Citation
  • BonocherCMMontenegroMLRosaESJCFerrianiRAMeolaJ2014Endometriosis and physical exercises: a systematic review. Reproductive Biology and Endocrinology124. (doi:10.1186/1477-7827-12-4)

    • Search Google Scholar
    • Export Citation
  • BourlevVIljasovaNAdamyanLLarssonAOlovssonM2010Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. Fertility and Sterility945257. (doi:10.1016/j.fertnstert.2009.02.019)

    • Search Google Scholar
    • Export Citation
  • BoyrazGSelcukIYaziciogluATuncerZS2013Ovarian carcinoma associated with endometriosis. European Journal of Obstetrics Gynecology and Reproductive Biology170211213. (doi:10.1016/j.ejogrb.2013.06.001)

    • Search Google Scholar
    • Export Citation
  • Braza-BoilsAGilabert-EstellesJRamonLAGilabertJMari-AlexandreJChirivellaMEspanaFEstellesA2013Peritoneal fluid reduces angiogenesis-related microRNA expression in cell cultures of endometrial and endometriotic tissues from women with endometriosis. PLoS ONE8e62370. (doi:10.1371/journal.pone.0062370)

    • Search Google Scholar
    • Export Citation
  • Braza-BoilsAMari-AlexandreJGilabertJSanchez-IzquierdoDEspanaFEstellesAGilabert-EstellesJ2014MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors. Hum Reproduction29978988. (doi:10.1093/humrep/deu019)

    • Search Google Scholar
    • Export Citation
  • Braza-BoilsASalloum-AsfarSMari-AlexandreJArroyoABGonzalez-ConejeroRBarcelo-MolinaMGarcia-OmsJVicenteVEstellesAGilabert-EstellesJ2015Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis. Human Reproduction3022922302. (doi:10.1093/humrep/dev204)

    • Search Google Scholar
    • Export Citation
  • BrintonLAGridleyGPerssonIBaronJBergqvistA1997Cancer risk after a hospital discharge diagnosis of endometriosis. American Journal of Obstetrics and Gynecology176572579. (doi:10.1016/S0002-9378(97)70550-7)

    • Search Google Scholar
    • Export Citation
  • BrintonLASakodaLCShermanMEFrederiksenKKjaerSKGraubardBIOlsenJHMellemkjaerL2005Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiology Biomarkers & Prevention1429292935. (doi:10.1158/1055-9965.EPI-05-0394)

    • Search Google Scholar
    • Export Citation
  • BrownJFarquharC2015An overview of treatments for endometriosis. JAMA313296297. (doi:10.1001/jama.2014.17119)

  • Bruner-TranKMcConahaMOsteenK2012Models of endometriosis: animal models I – rodent-based chimeric models. In Endometriosis: Science and Practice.Chichester, UK: Wiley-Blackwell. (doi:10.1002/9781444398519.ch26)

    • Search Google Scholar
    • Export Citation
  • BukulmezOHardyDBCarrBRWordRAMendelsonCR2008Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology14911901204. (doi:10.1210/en.2007-0665)

    • Search Google Scholar
    • Export Citation
  • BulunSE2009Endometriosis. New England Journal of Medicine360268279. (doi:10.1056/NEJMra0804690)

  • BulunSEMonsavaisDPavoneMEDysonMXueQAttarETokunagaHSuEJ2012Role of estrogen receptor-beta in endometriosis. Seminars in Reproductive Medicine303945. (doi:10.1055/s-0031-1299596)

    • Search Google Scholar
    • Export Citation
  • BulunSEMonsivaisDKakinumaTFurukawaYBernardiLPavoneMEDysonM2015Molecular biology of endometriosis: from aromatase to genomic abnormalities. Seminars in Reproductive Medicine33220224. (doi:10.1055/s-0035-1554053)

    • Search Google Scholar
    • Export Citation
  • BurneyROTalbiSHamiltonAEVoKCNyegaardMNezhatCRLesseyBAGiudiceLC2007Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology14838143826. (doi:10.1210/en.2006-1692)

    • Search Google Scholar
    • Export Citation
  • BurnsKARodriguezKFHewittSCJanardhanKSYoungSLKorachKS2012Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model. Endocrinology15339603971. (doi:10.1210/en.2012-1294)

    • Search Google Scholar
    • Export Citation
  • CarmonaFChapronCMartinez-ZamoraMASantulliPRabanalAMartinez-FlorensaMLozanoFBalaschJ2012Ovarian endometrioma but not deep infiltrating endometriosis is associated with increased serum levels of interleukin-8 and interleukin-6. Journal of Reproductive Immunology958086. (doi:10.1016/j.jri.2012.06.001)

    • Search Google Scholar
    • Export Citation
  • CarrBJOchoaLRankinDOwensBD2009Biologic response to orthopedic sutures: a histologic study in a rabbit model. Orthopedics32828. (doi:10.3928/01477447-20090922-11)

    • Search Google Scholar
    • Export Citation
  • CarrBDmowskiWPO’BrienCJiangPBurkeJJimenezRGarnerEChwaliszK2014Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reproductive Sciences2113411351. (doi:10.1177/1933719114549848)

    • Search Google Scholar
    • Export Citation
  • ChenSQLiJBJiangHYYuanLNiuGYaoSZ2013aExpression of human beta-defensin-2 in the eutopic and ectopic endometrial tissues in patients with endometriosis.Archives of Gynecology and Obstetrics28711511157. (doi:10.1007/s00404-012-2686-7)

    • Search Google Scholar
    • Export Citation
  • ChenYJWuHHLiauWTTsaiCYTsaiHWChaoKCSungYJLiHY2013bA tumor necrosis factor-alpha inhibitor reduces the embryotoxic effects of endometriotic peritoneal fluid. Fertility and Sterility10014761485. (doi:10.1016/j.fertnstert.2013.07.1985)

    • Search Google Scholar
    • Export Citation
  • ChenSWuRFSuLZhouWDZhuMBChenQH2014Lipoxin A4 regulates expression of the estrogen receptor and inhibits 17beta-estradiol induced p38 mitogen-activated protein kinase phosphorylation in human endometriotic stromal cells. Fertility and Sterility102264271. (doi:10.1016/j.fertnstert.2014.03.029)